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Abstract 
MicroRNA-21 (miR-21) is important for maintaining optimal ovulation rates and granulosa cell viability.  
It is also upregulated in human uterine leiomyomas (ULMs), a disease characterized by the presence of 
benign tumors on the myometrium.  The primary objective of this thesis was to identify miR-21 direct 
targets in granulosa cells that mediate its important ovarian functions.  The secondary objective was to 
elucidate the role of miR-21 in ULMs.  Gene expression and bioinformatic analysis performed on 
granulosa cells after miR-21 inhibition identified many potential miR-21 direct targets.  Luciferase assays 
revealed that miR-21 regulates the 3’Untranslated Region (3’UTR) of apolipoprotein B mRNA editing 
enzyme catalytic polypeptide 3 (Apobec3), intestinal-specific homeobox (ISX) and ubiquitin-specific 
protease 30 (USP30).  Further research of ISX revealed that miR-21 binds to its 3’UTR and over 
expression of miR-21 causes inhibition of ISX protein levels.  Quantitative RT-PCR and western analysis 
revealed that ISX regulates scavenger receptor class B type 1 (SRB1) β,β-carotene 15,15′-monooxygenase 
1 (BCMO1) and retinoic acid receptor α (RARα) in granulosa cells, genes known to be involved in 
steriodogenesis, embryogenesis and meiotic resumption in the ovary, respectively.  Therefore, miR-21 
may be regulating these functions through directly targeting ISX in granulosa cells.  Investigation of miR-
21 in UtM and UtLM cell lines (cell lines derived from myometrial and leiomyoma tissue, respectively) 
showed that miR-21 inhibits phosphorylation of elongation factor 2 and prevents expression of cleaved 
caspase 3 in both cell lines; findings which suggest that miR-21 is important for preventing cell death and 
maintaining cellular translation in these cell lines.  Further research showed that miR-21 inhibits 
expression of programmed cell death 4 (PDCD-4).  Expression analysis of PDCD-4 showed that it is 
highly expressed in ULM tissue when compared to paired healthy myometrial tissue.  Since PDCD-4 is a 
known tumor suppressor that is suppressed in tumors, this finding indicates that PDCD-4 is playing an 
alternative role in ULMs compared to other tumorigenic tissue.  Since miR-21 is also overexpressed in 
ULMs, miR-21 is excluded as a means of post-transcriptional gene control that gives rise to PDCD-4 
induction in ULMs.  Together these studies have identified novel direct targets for miR-21 in granulosa 
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cells and implicated one of miR-21’s most well-studied direct targets, PDCD-4 in a novel functional role 
in ULMs.      
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1.  Post-Transcriptional Gene Regulation and MicroRNA 
The concept of post-transcriptional gene regulation playing a critical role in protein expression was 
proposed at least as far back as 1969 [1].  Subsequent studies have shown that there is a lack of 
correlation between steady-state levels of mRNA and the proteins encoded by these mRNA [2, 3] 
indicating that post-transcriptional gene regulation is an important form of cellular gene control.  In 1993, 
a new class of post-transcriptional gene regulators, microRNA, were discovered [4, 5].  Since their 
discovery, hundreds of plant and animal microRNA have been identified, which have been shown to be 
critical mediators of diverse physiological and pathological functions including developmental timing [4-
8] organogenesis [9-12], differentiation [11-15], programmed cell death [16-18] embryogenesis [16, 17, 
19-21], neurogenesis [15], angiogenesis [11], hematopoiesis [12] , exocytosis [22], tumorigenesis [23, 
24], viral defense [25]and insulin secretion [22].  
MicroRNA biogenesis occurs through a multi-step process (Figure V-1).  Transcription of microRNA 
typically occurs by polymerase II (pol II) and atypically by polymerase III [26, 27].  Pol II transcribed 
microRNA contain, similar to mRNA,  5’ cap structures, are polyadenylated and may be spliced [26, 28].  
After transcription, the microRNA, in its pri-microRNA/immature form, gets processed in the nucleus by 
a multiprotein complex that contains the RNase III enzyme Drosha and the double stranded RNA binding 
domain protein DGCR8/Pasha [29].  This complex cleaves the pri-microRNA stem creating a 70 
nucleotide precursor microRNA (pre-microRNA) [29].  The pre-microRNA contains a 2 nucleotide 3’ 
overhang that is recognized by exportin 5, which transports the pre-microRNA into the cytoplasm [30].  A 
RNase III enzyme, Dicer, cleaves the pre-microRNA hairpin loop to produce the 22 nucleotide 
microRNA:microRNA duplex [31, 32].  The duplex along with Dicer binds to the argonaute protein Ago2 
to form the RNA induced silencing complex (RISC) [33].  The miRNA strand with the higher stability at 
its 5’ end is degraded while the strand with the lower stability is incorporated into the RISC where it can 
post-transcriptionally regulate gene expression [34, 35].  
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Figure V-1.  MicroRNA biogenesis schematic showing compartmental process of the pri-microRNA and 
the pre-microRNA that takes place in the nucleus and cytoplasm, respectively.  Drosha in the nucleus and 
Dicer in the cytoplasm are two RNase III enzymes important for successful biogenesis of microRNA into 
its mature form.  Exportin five transports the pre-microRNA out of the nucleus.  After successful 
biogenesis the mature microRNA binds to argonaute 2 where it can post-transcriptionally regulate gene 
expression [36]. 
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Figure V-I 
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MicroRNA regulate gene expression through incorporation into the RISC [37, 38].  Extensive studies 
have shown that microRNA/RISC target the 3’UnTranslated Region (3’UTR) of an mRNA to which the 
microRNA has complementarity [39-43].  The first animal miRNA targets were identified in 
Caenorhabditis elegans, which showed that lin-4, the 1
st
 identified microRNA, bound to a complementary 
sequence in the 3’UTR of lin-14 [4, 5].  Early investigations showed that this binding event regulated 
gene expression through translational repression having no effect on steady-state mRNA levels [4, 5, 44, 
45].  One study showed that Let7a microRNA repressed targets were all skewed to the top of the 
polysomal gradients where mRNA are not translated while the repressed mRNAs and argonaute proteins 
accumulated in processing bodies [39]. This indicated that Let7a regulated its targets through translational 
repression.  More recent investigations, however, have revealed that mRNA destabilization and repression 
are prominent mechanisms by which microRNA regulate gene expression [14, 40-42].  A study 
investigating miR-122 and its target Cat-1, showed that miR-122 repression of Cat-1 protein caused 
moderately reduced levels of Cat-1 mRNA levels [14].  Further investigations have revealed that 
microRNA cause widespread, albeit moderate, changes in mRNA expression levels [41, 46].  One 
seminal study showed that down regulated mRNA caused by overexpression of a microRNA were 
overrepresented with sequence motifs in their 3’UTR that were complimentary to the overexpressed 
microRNA [42], suggesting that, at least, some microRNA direct targets show changes in their steady-
state mRNA expression.      
To help identify direct targets of microRNA, prediction algorithms have been developed.  Studies have  
shown that free energy of microRNA/mRNA duplex as well as conservation of target sites in related 
genomes are important in determining specificity and efficiency of binding between microRNA and 
mRNA 3’UTRs [43, 47, 48].  These algorithms have evolved with the newest iterations starting in 2003, 
which have now factored in these experimentally derived concepts [21, 49-52].  Two published studies, 
showed that previously published microRNA/mRNA binding reactions could be identified using the 
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newest iterations of these algorithms [21, 50].  This finding suggests that it is possible to identify 
microRNA/mRNA binding events using these algorithms.   
These computational methods have suggested that there are two classes of microRNA targets.  The first 
class has perfect sequence complementarity of the mRNA target sequence to that of the 5’ end of the 
microRNA (typically this perfect complementarity consists of seven consecutive nucleotides at the 5’ end 
of the microRNA) and does not require additional base pairings [19, 50, 53, 54].  The second class has 
imperfect pairing at the 5’ end that is compensated with additional pairing at the 3’ end of the microRNA 
[19, 50, 53, 54].  Studies in vertebrates, flies and nematodes showed that detectable sites in the first class 
were more abundant than that of the second class and that these sites were conserved across species [53].  
Algorithms that factor in both classes of microRNA/mRNA target recognition and that utilize cross-
species conservation within its algorithm, suggest that there is widespread similarity of genes regulated by 
microRNA between insects and vertebrates as well as between flies and mammals  [53].  Computational 
algorithms that emphasize cross-species conservation, predict 80-90 percent of the same microRNA 
binding sites when the same data sets of human 3’UTRs were filtered through their respective algorithms 
[49, 53].  Together these algorithms estimate that, at least, 30% of all human 3’UTRs are regulated by 
conserved microRNA [54, 55].   A newer method, which does not factor in cross species conservation, 
predicts that 74% to 94% of gene transcripts may be microRNA targets [56].  This method, however, has 
yet to be investigated to determine its efficacy in predicting microRNA/mRNA binding events.   
2.  Hormonal and Transcriptional Regulation of the Female Reproductive Tract 
The female reproductive tract is important for the maturation of fertilizable oocytes, sperm capacitation, 
fertilization, embryological development, implantation, gestation and parturition.  Steroid and peptide 
hormones as well as appropriately timed changes in gene expression within the ovary, oviduct and uterus 
are required for proper female reproductive tract function [57-65].   Abnormalities within this system can 
cause dysfunction and disease within and outside the tract [57, 66-68]. 
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Within the oviduct, ovarian steroids cause morphological and biochemical changes that are important for 
fertilization and embryonic development [69, 70].  Studies have also shown that several oviductal proteins 
are induced and secreted within the oviduct that are important for binding of sperm and oocyte, sperm 
penetration and early embryological development [69, 70].  In the uterus, the interplay of ovarian, 
pituitary and peptide hormones transform the endometrium of the uterus to a stage in which it is receptive 
to the blastocyst [71-73].  This hormonal regulation of the uterus causes widespread transcriptional 
changes in gene expression critical for implantation of the blastocyst [71-73].  
In the ovary, both FSH and LH from the pituitary are important for oocyte development and ovulation.  
FSH induces many transcriptional changes as well as an increase in estradiol production, which 
eventually leads to the luteinizing surge of LH [74-77].  The surge leads to changes in gene expression, an 
increase antrum volume and follicular size and further maturation of the oocyte [74-77].  Eventually there 
is a breakdown of the ovarian cumulus layer surrounding the oocyte within the follicle allowing for 
ovulation of a fertilizable oocyte [78, 79].  Following ovulation the corpus luteum forms, which secretes 
progesterone, which is critical hormonal stimulation critical for maintenance of the early stages of 
pregnancy [80]. 
The period of time between the initiation of the LH surge and ovulation is the periovulatory period.  
During this period, LH acts on periovulatory follicles, which are mature follicles within the ovary capable 
of responding to the LH surge [75].  Within periovulatory follicles mural granulosa cells line the follicular 
wall and contain LH receptors while cumulus granulosa cells surround the oocyte and do not contain LH 
receptors [81].  Regulation of mural cells occurs through LH binding to its receptor, which leads to an 
increase in cyclic AMP and intracellular calcium levels [82, 83].  This causes stimulation of many 
pathways including PKA and MAPK/ERK [84-87] leading to vast changes in gene expression through 
transcriptional control [88-92].        
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3.  MicroRNA Regulation of Female Reproductive Tract     
Recent research has shown that in addition to hormonal and transcriptional regulation, the female 
reproductive tract is also, in part, under the regulation of post-transcriptional gene regulatory mechanisms.  
There have been multiple studies in which Dicer, the cytoplasmic RNAse III enzyme critical for 
microRNA biogenesis was inactivated or downregulated in the Mullerian duct mesenchyme of the female 
reproductive tract in the mouse.  Each of these studies resulted in a significant reproductive phenotype 
[93-95].  Gonzalez et al, showed that there was a reduction in the size of the uterine horns and oviducts 
and that cysts formed in the oviducts at the isthmus near the uterotubular junction (the junction that 
connects the oviduct to the uterus) [93].  These cysts caused impaired transport of oocytes as evidenced 
by the identification of unfertilized degenerate oocytes found within the cysts [93].  Beads transferred into 
the mutant oviduct also failed to transport to the uterus further suggesting that Dicer inactivation was 
causing impaired oocyte and embryo transport with the oviduct [93].  This study also identified a uterine 
phenotype, showing a reduction in glandular tissue and that the remaining glandular tissue was localized 
to the myometrium as opposed to its normal location in the endometrium [93].   This uterine phenotype is 
similar to a rare medical condition found in women known as adenomyosis in which ectopic endometrium 
is found in the myometrium [93].  This ectopic endometrial expression identified in these mutant mice is 
correlated with the ectopic expression of Wnt4 and Wnt5a in 8-week old female mice, which was not 
observed in wild type mice [93].  It is possible, as the authors point out, that this unique myometrial 
expression pattern of Wnt genes could be causing adenomyosis-like phenotype found in their mutant mice 
[93]. 
A study performed by Hong et al, also inactivated Dicer in the Mullerian duct mesenchyme of the female 
reproductive tract in the mouse [94].  Morphological analysis also showed that the uterus was 
hypertrophic and the oviduct was highly disorganized [94].  Fertilization did occur when knockout mice 
were bred to wild type fertile males [94].  In addition fertilized oocytes recovered on day 1 of pregnancy 
could be successfully developed to the blastocyst stage in culture [94].  However, fertilized oocytes 
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recovered on day 3 of pregnancy showed developmental defects when compared to wild type controls 
[94].  Similar to the Gonzalez et al study, there was impaired oviductal transport as there was no evidence 
of implantation on day 4 of pregnancy [94].  When wild type, fertile males were bred to the Dicer1 
knockout females over a 5 month period normal mating behavior was displayed but no offspring resulted, 
indicating that Dicer is essential for fertility in female mice [94].  
A third study performed by Nagaraja et al also inactivated Dicer in the Mullerian ducts and in the 
mesenchyme of female mice.  Similar to findings described above there was compromised oocyte and 
embryo quality as well as impaired transport in the oviduct [95].  Knockdown of Dicer also caused 
prominent oviductal cysts and shorter uterine horns similar to findings in the studies described above 
[95].  Again similar to the two previously described studies, Dicer inactivation lead to female sterility 
[95].  Nagaraja et al, also identified genes that were induced as a result of dicer knockdown that are 
potential direct targets of microRNA [95].  Additionally members of the wingless family of secreted 
glycoproteins (WNT) as well as homeobox transcription factors (both of which function in Mullerian duct 
differentiation and maturation) were both induced as a result of Dicer knockdown [95]. 
A study performed by Otsuka et al investigated Dicer function in the female reproductive tract using an 
alternative approach in which a hypomorphic Dicer 1 allele was used to cause Dicer deficiency in the 
whole animal.  This method led to corpus luteum insufficiency that, in part, was due to inadequate 
vascularization in the ovary [96].  Further analysis showed that adding back the microRNA miR-17-5p 
and Let-7b after Dicer knockdown, partially restored corpus luteum function [96].  Together these studies 
implicate dicer, and thereby microRNA, as being critical to proper female reproductive function.   
 
4.  MicroRNA-21 (miR-21) in the Ovary and Granulosa Cells 
Studies from our lab have further investigated the importance of microRNA in the ovary using mouse 
models.  Specifically our lab identified microRNA that are regulated in granulosa cells by human 
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chorionic gonadotropin (hCG), a bioequivalent of LH [97].  Of the 212 microRNA that were shown to be 
expressed in granulosa cells, 13 were dysregulated 4 hours after hCG/LH induction compared to control 
animals that were not stimulated [97].  Of these 13, 10 were inhibited including miR-483, miR-491, miR-
484, miR-329, miR-433-3p, miR-532, miR-431, miR-672, miR-351 and miR-99b [97], while three were 
induced; miR-132 (16.9-fold), miR-212 (21.7-fold) and miR-21 (4-fold) [97].  QRT-PCR analysis 
showed that 4 hours after hCG/LH treatment miR-132, miR-212 and miR-21 were 11.4-, 20.5- and 4.0-
fold upregulated, respectively [98].  Analysis of the immature forms of each showed that the precursor 
forms were upregulated prior to or commensurate with that of mature forms, suggesting that hCG/LH is 
transcriptionally regulating miR-132, miR-212 and miR-21 [97].  Both the precursor and mature forms of 
each microRNA remain elevated throughout the periovulatory period [97].    
Further investigation into miR-21 revealed that it had an important function in the ovary and granulosa 
cells.  Inhibition of miR-21 using a locked nucleic acid, which is an oligo complementary to miR-21 
(LNA-21) in cultured granulosa cells caused upregulation of cleaved caspase 3 at 8 hours and 24 hours 
post-transfection while there was no increase in this apoptotic marker in control treated cells treated with 
a non-specific LNA (LNA-NS) [99].  Annexin V staining of granulosa cells subsequent to transfection, 
using the same experimental and control treatments, showed that there was a decrease in cell survival 
starting at 8 hours post-transfection and that at 24 hours post-transfection only 60% of the cells were alive 
[99].  Bright field imaging of cells 24 hours after LNA-21 treatment showed the cells rounding up and 
lifting off the plate (Figure V-2), indicating cell death, while LNA-NS treated cells showed no such 
phenotype [99].  To confirm that this in-vitro effect occurred in-vivo, 19-day old, immature, female CF-1 
mice undergoing a standard 46hr PMSG/16 hr hCG treatment protocol were injected with saline (control) 
or LNA-21 into the ovarian bursa, 24 hours after PMSG treatment.  Sixteen hours after hCG treatment 
animals were sacrificed and ovaries were isolated and sectioned.  TUNEL staining revealed an increase in 
apoptosis in the LNA-21 treated ovaries [99].    
11 
 
Figure V-II.  Bright field imaging of granulosa cells 24 hours after transfection with a non-specific LNA 
(LNA-NS) (control) and an LNA specific for miR-21 (LNA-21) (a locked nucleic acid that binds and 
inhibits miR-21 activity).  Treatment with LNA-21 caused granulosa cells to round up and begin lifting 
off plate indicating that cells were dying.  Cells treated with LNA-NS showed no such phenotype [99]  
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Figure V-II 
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Due to its important anti-apoptotic and pro-ovulatory roles, targets and pathways downstream of miR-21 
were investigated.  Cultured granulosa cells were treated with anti-NS (control) and anti-21 and labeled 
Cy3 (anti-NS) and cy5 (anti-21).  Protein lysates isolated from cells were subjected to 2-dimensional gel 
electrophoresis and fluorescent analysis, followed by mass spectrometry.  Results showed that 
phosphorylated forms of elongation factor 2 (EF-2) were upregulated as a result of anti-21 treatment 
(unpublished data).  This finding was confirmed through western analysis, which revealed that phospho-
EF-2 is induced in granulosa cells after treatment with anti-21 (unpublished data).   EF-2 is an important 
factor in global translational regulation and when it is phosphorylated global translation is prevented due 
to EF-2’s inability to bind to the ribosome [100, 101].  Induction of phospho-EF-2 after miR-21 inhibition 
suggests that miR-21 activity is critical for maintaining global translation.  Knockdown of miR-21 caused 
a 3-fold decrease in the amount of S
35
 methionine incorporation in granulosa cells, compared to that of 
control treatments; providing further confirmation that miR-21 is regulating cellular translation 
(unpublished data).  Further investigation revealed that factors within the AKT pathway (a pathway 
immediately upstream of EF-2) including AKT, TSC2, mTOR, p70S6K and 4EBP1 had reductions in 
their phosphorylation states after miR-21 inhibition in granulosa cells (unpublished data).  This finding 
indicates that miR-21 activity is critical for maintaining this pathway in its active form and potentially 
reveals the mechanism through which miR-21 inhibits phosphorylation of EF-2, thereby maintaining this 
gene in its active state. 
5.  MicroRNA-21 (miR-21) in Cancer 
Many studies that have implicated miR-21 as being a critical factor in cancer.  MiR-21 was originally 
shown to be overexpressed in human glioblastoma in both high grade glioma samples from humans as 
well as a number of glioblastoma cell lines [102].  Subsequent studies investigating a vast array of cancers 
including hepatocellular [103], gastric cancer [104], ovarian cancer[105, 106], cervical carcinoma [107], 
head and neck cancer cell lines [108] papillary thyroid carcinoma [109], chronic lymphocytic leukemia 
[110] and diffuse large B cell lymphoma [111] have all shown miR-21 induction.  In addition a study 
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examining aberrant microRNA expression across 540 human samples representing 6 solid tumors, 
showed that miR-21 was the only microRNA upregulated in all tumor types [112].  
There have also been a few studies examining miR-21’s mechanism of induction in cancer.  Human miR-
21 has been mapped to the locus 17q23.2 where it overlaps with TMEM49, a protein encoding gene [26, 
113].  Amplification of this chromosomal region has been linked to a number of cancers including breast 
[114], Hodgkins lymphoma [115], pediatric brain tumors [116] and prostate cancer [117].  Studies have 
shown that 17q locus induction is, however, not concomitant with upregulation of the miR-21 locus [110, 
118].  This suggests that, while miR-21 and the 17q locus tend to be induced in cancer, the two are under 
separate regulatory control.  Studies that have investigated transcriptional regulation of miR-21 and have 
shown that it is transcribed independently of TMEM49, suggesting that miR-21 is under different 
transcriptional control than the gene within which it is embedded [113].   This finding is consistent with 
our results that have shown that while LH does upregulate miR-21, TMEM49 expression levels remain 
similar between LH treated and non-LH treated ovaries [99].   
Previous studies have shown that transcription of miR-21 occurred through the classical biogenesis 
pathway producing a capped, polyadenylated and unspliced pri-microRNA ~3.5kb in length [26].   
Transcriptional regulation of miR-21 has been found to occur through multiple, highly conserved 
enhancer elements including activator protein 1 (AP-1), C/EBP, nuclear factor 1 (NF-1), Ets/PU.1 and 
signal transducer and activator of transcription 3 (STAT3) amongst others [113].  Studies have shown that 
binding to these elements within the miR-21 promoter can be either inhibitory, as in the case of NF-1 and 
CEPB/β, or stimulatory as in the case of AP-1 and STAT3 [113, 119-121].  It has also been shown that 
factors can transcriptionally regulate miR-21 in one cell type but not in another.  RE-1-silencing 
transcription factor (REST) blocks miR-21 in mouse embryonic stem cells [122], but does not regulate 
miR-21 in the Hdh7/7 cell line [123], a cell line derived from embryonic striatum.    
15 
 
Determining transcriptional control of miR-21 is critical because induction of miR-21 in cancer is in part 
through transcriptional regulation [124].  This is unique in that most microRNAs that are dysregulated in 
cancer do so without changes in their primary precursors [125], suggesting that the majority of cancer 
mediated dysregulation of microRNA takes place after transcription.  Profiling of microRNA across 
human cancers has shown that most microRNA dysregulated in cancer are downregulated [124].  One 
interpretation of these findings is that, in addition to induction of the precursor form of miR-21, that 
overexpression of miR-21 in cancer may be due to its precursor being a preferential substrate for Drosha 
and/or Dicer.    
Due to its ubiquity in cancer a number investigations have been initiated to determine miR-21’s direct 
targets and functions.  This has resulted in identification of numerous miR-21 direct targets.  These 
include phosphatase and tensin homologue (PTEN) [126, 127], reverse-inducing-cysteine-rich protein 
with kazal motifs (RECK) [128], tissue inhibitor of metalloproteinases (TIMP) [128], leucine rich repeat 
interacting protein 1 (LRRFIP1) [129], bone morphogenetic protein receptor II (BMPR II) [130], ras 
homologue gene family member b (RHOB) [131], sprouty2 (SPRY2) [132], mapsin [133], tropomyosin 1 
(TPM1) [133, 134] and programmed cell death 4 (PDCD-4) [133, 135, 136].  These targets have been 
identified across a variety of cell lines including PTEN in cardiac fibroblasts [126] and non-small lung 
cancer cell lines [127], RECK, TIMP and LRRFIP1 in glioma cells [128, 129], BMPRII in prostate 
cancer cells [130], RHOB in hepatocellular and breast cancer cell lines [131], SPRY2 in cardiac myocytes 
[132] and mapsin, TPM1 and PDCD-4 in breast cancer cell lines [133, 134].  These targets are known to 
regulate tumor progression, invasion, migration, cell growth and proliferation indicating that miR-21 may 
function to regulate these processes in cancer. 
Due to miR-21’s functional importance in granulosa cells, some of its previously identified direct targets 
in cancer cells were investigated in granulosa cells.  At 4, 8 and 24 hours after miR-21 inhibition by 
LNA-21 there was no change in the protein expression levels of PDCD-4, PTEN, TPM1 and SPRY2 
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when compared to the LNA-NS treated cells [99], suggesting that miR-21 is not directly targeting these 
genes in granulosa cells. 
In addition to identification of its direct targets, studies of miR-21 in cancer have revealed that it has 
oncogenic functions.  Overexpression of miR-21 in hepatocellular cancer cell lines caused increased 
proliferation, migration and invasion [137].  Induction of miR-21 in MCF-7 breast carcinoma cells and 
JB6 epidermal cancer cells caused an increase in anchorage independent colony formation, which models 
neoplastic transformation [138].  Elevation of miR-21 increased the survival rate of myeloma cells [119].  
Inhibition studies have shown that when miR-21 expression is reduced there is a decrease in proliferation 
and growth of MCF-7 cells [135, 139] as well as reduced invasion, intravasation and metastatic capacity 
of colon cancer cells [140].  There is also a reduction in anchorage-independent colony formation and an 
induction in apoptosis when miR-21 is reduced [137, 141].  Studies have also shown that miR-21 
mediates chemoresistance through the upregulation of pathways that mediate antiapoptotic activity [142, 
143].  Together these studies suggest there is a causal and mechanistic link between induction of miR-21 
and the maintenance and progression of cancer. 
6.  Programmed Cell Death 4 (PDCD-4) 
PDCD-4 has emerged as one if miR-21’s most well-studied direct targets [133, 135, 136, 138, 144-147].  
PDCD-4 is a known tumor suppressor that inhibits tumor progression via the inhibition of translation 
[148].  It contains domains that bind with the scaffolding protein, eukaryotic protein synthesis initiation 
factor 4G, and the RNA helicase, eukaryotic protein synthesis initiation factor 4A; binding events which 
inhibit the initiation of translation [149, 150].  Investigations have also shown that PDCD-4 is able to 
shuttle between the nucleus and cytoplasm and that it contains domains which bind RNA [151], 
suggesting that PDCD-4 is involved in RNA regulation and/or metabolism.  Importantly, studies have 
linked mouse and human carcinogenesis to inhibition of PDCD-4 expression [152-154].  Exposure of 
mice to the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate, decreases protein levels of PDCD-4 
in skin papillomas and this decrease is attributable to increased proteasomal degradation mediated 
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through activation of the mTOR pathway [154].  In addition transgenic mice that overexpress PDCD-4 in 
their epidermis were less susceptible to papilloma formation, carcinoma incidence and papilloma-to-
carcinoma conversion than their wild type counterparts exposed to the same carcinogenesis protocol 
[153].  Global knockdown of PDCD-4 causes the development of spontaneous lymphoma in mice and a 
significant reduction in life-span [155].  These in-vivo findings have been supported by in-vitro evidence 
in which exposure of HEK293 cells and keratinocytes to carcinogenesis protocols had decreased levels of 
PDCD-4 [154].  Furthermore JB6 epidermal cell lines overexpressing PDCD-4 were resistant to 
neoplastic transformation [152].  Also, AP-1 dependent transcription, an event required for tumorigenesis, 
is inhibited by PDCD-4 both in-vivo and in-vitro [152, 153]. 
7.  Human Uterine Leiomyomas (ULMs) 
ULMs are benign tumors located in the myometrium.  They have an overall lifetime incidence rate of 
between 70% and 80% and are clinically apparent in ~25% of reproductive aged women [156].  ULMs 
manifest through a variety of symptoms including abdominal and pelvic pain, urinary incontinence, 
abnormal uterine bleeding and constipation [157, 158].  ULMs are also correlated with reproductive 
abnormalities and can lead to spontaneous abortions and infertility [159].  ULMs are the cause of 30% of 
all hysterectomies in the U.S. leading to over 200,000 annually [160].   Most women who are diagnosed 
with ULMs contain multiple tumors within their uterus, which are classified according to their location.  
The intramural fibroid is the most common tumor and is located in the smooth muscle of the uterine wall 
[161].  Less common are tumors located on the uterine surface (subserosal) and the uterine cavity 
(submucousal) [161]. 
Through many clinical and epidemiological studies several risk factors have been identified in ULMs.  
One study showed that young girls who have an early onset of menarche (at or before the age of 10) are at 
an increased risk to develop ULMs [162].  Multiple clinical studies have shown that parous women are at 
a lower risk of developing ULMs than nulliparous and that there is a progressive decline in risk with 
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increasing number of births [162-166].  Increase in age is also positively correlated with higher ULM 
incidence with a significant increase in diagnosis with women in their forties [165, 167-169].  Menopause 
has been shown to be a negatively correlated with ULMs as well as a reduced risk of surgery caused by 
ULMs [163, 165, 170].  Several epidemiological studies have revealed that obesity is correlated with an 
increased incidence of ULMs [164, 165, 171-175].  Race is also believed to contribute to ULM incidence 
with African American women having a higher risk of developing the disease than their Caucasian 
counterparts [167, 176-180].        
It is believed that somatic mutations of normal myometrium lead to ULMs [181].  Both hormones and 
local growth factors have been implicated in driving these mutations.  Estrogen is believed to be a major 
stimulus of ULM growth and it is quite common for women who have fibroids to have their tumors 
shrink when they undergo menopause (A time period in which women produce less estrogen) [182, 183].  
More recent studies have implicated progesterone as playing an important role in fibroid growth [184, 
185].  Treatments in which both estrogen and progesterone are reduced by inhibiting gonadotropin release 
have been effective in reducing tumor size [186].  In addition mifepristone, an anti-progesterone, has also 
proven effective in tumor reduction [187].   
In addition to steroids several mitogenic growth factors have been shown to be elevated in ULMs when 
compared to healthy myometrial tissue.  These include transforming growth factor-β, basic fibroblast 
growth factor, epidermal growth factor, platelet derived growth factor and insulin like growth factor [188-
192].  Steroids often mediate their function through growth factors [59, 60, 193-195] and some studies 
have shown that sex steroids drive increased growth factor expression in ULMs [196-199]. 
Genetic predisposition has also been identified as a risk factor in the development of ULMs.  Around 40% 
of fibroids show chromosomal abnormalities and cytogenetic variation in chromosomes 6, 7, 12 and 14 
[161].  In addition, a gene mapping study implicated a specific breakage point on chromosome 12 as 
being critical in the pathobiology of fibroids [200].  Clinical evidence indicates that first degree relatives 
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in families with two or more verified leiomyoma cases are at a significantly higher risk of obtaining the 
disease than first degree relatives in families in which there are fewer than two relatives that have the 
disease [201]. 
While hormones, growth factors, genetics and other risk factors have been correlated with the disease, the 
etiology of ULMs remains unknown.  Recent profiling experiments have shown that ULMs have a 
distinct microRNA signature and that miR-21 is induced in ULMs when compared to paired health 
myometrial tissues [202-204].   
8.  Statement of Work 
Since previous reports from our lab implicated miR-21 as having pro-ovulatory and anti-apoptotic 
functions in granulosa cells, I wanted to elucidate fundamental molecular events that gave rise to these 
critical functions through identifying miR-21 direct targets in granulosa cells.  To identify these targets, 
miR-21’s effect on steady-state mRNA will be examined as previous reports have shown that microRNA 
direct targets can be regulated at the mRNA level.  The 3’UTR of each differentially expressed gene will 
be examined, using bioinformatic algorithms, to determine if it has a potential miR-21 binding site.  This 
should reveal a subset of miR-21 regulated genes that will be further tested using 3’UTR luciferase 
reporters, to identify bona fide miR-21 direct targets.    Due to miR-21’s critical functional roles in 
granulosa cells, I believe that these direct targets will be functionally relevant to granulosa cell 
physiology.  Additionally, miR-21 direct targets identified in this study will undergo further experimental 
analysis to evaluate their functional roles in granulosa cells.  Together these studies will begin to reveal 
the molecular via which miR-21 carries out its functions in granulosa cells. 
Lastly, since miR-21 has shown significant induction in ULMs, I will study the role of miR-21 in this 
uterine pathology.  Experiments will initially focus on miR-21’s regulation of PDCD-4 (a functionally 
significant miR-21 direct target in many cell lines) in a cell line derived from ULMs.  I will also 
determine expression patterns of both PDCD-4 and miR-21 in leiomyoma tissue and compare these 
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patterns to paired healthy myometrial tissue.  This study has the potential to yield insights into miR-21 
function in a prevalent reproductive disease and inform us as to whether cellular context impacts miR-21 
effects.        
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VI. Chapter 2: Identification of MicroRNA-21 (miR-21) Direct Targets in 
Granulosa Cells 
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1.  Abstract 
MicroRNA-21 (miR-21) is important for maintaining granulosa cell viability and optimal ovulation rates.  
To being to elucidate the mechanism by which miR-21 affects these functions, this study sought to 
identify miR-21’s direct targets in granulosa cells.  To do so, mouse cultured granulosa cells were treated 
with an inhibitory nucleotide specific for miR-21 (LNA-21) and a non-specific LNA (LNA-NS), used as a 
control.  At 2, 4 and 8 hours after treatment, arrays were performed to determine differential gene 
expression analysis between the LNA-NS and the LNA-21 treated cells.  Array analysis showed that loss 
of miR-21 caused dysregulation of 1,950 genes between 1.2- and 3.0-fold across the 3 time points.  Of the 
1,950 genes, 357 were overexpressed and had at least one potential miR-21 site in their 3’utr according to 
the algorithms microR, miRanda, PicTar, PITA and TargetScan.  Due to their involvement in apoptosis, 
cell differentation and transformation, 9 of the 357 genes were further analyzed to determine if they were 
miR-21 direct targets.   These included apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 
(Apobec3), calcium-sensing receptor (CASR), cyclin E1 (CCNE1), tetraspanin CD151 (CD151), 
intestinal-specific homeobox (ISX), galectin 3 (LGALS),T-lymphoma invasion and metastasis inducing 
protein (TIAM1), ubiquitin-specific protease 30 (USP30) and WD40-repeat protein (WDR5).  The 3’ 
Untranslated Region (3’UTR) of each gene was separately cloned into a luciferase expression vector and 
cotransfected into granulosa cells along with either pre-miR-21 (a miR-21 overexpression oligo) or pre-
miR-NS (control oligo).  Overexpression of miR-21 caused a significant reduction in the renilla/firefly 
ratio of Apobec3, ISX and USP30, suggesting that miR-21 was regulating these genes and implicating 
them as miR-21 direct targets.   There was no difference in the renilla/firefly ratios between cells treated 
with the miR-21 overexpression oligo and the control oligo in the 6 other genes tested.  Apobec3, USP30 
and ISX are important factors in mitochondrial morphology, innate immunity and vitamin A regulation, 
respectively.  Direct regulation of these genes may mean that miR-21 is regulating these functions in 
granulosa cells.  This study is the first to identify miR-21 direct targets in granulosa cells; identification of 
which is critical first step to elucidating miR-21’s mechanism of action in granulosa cells. 
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2.  Introduction 
MicroRNA are ~22 nucleotide regulatory RNA that function in cell proliferation, cell death, neuronal 
patterning and modulation of hematopoietic lineage differentiation, amongst other functions [205].   
Additionally microRNA play important roles in reproduction including the production of healthy 
oocytes/embryos, proper transport and implantation of embryos/blastocysts as well as optimal ovulation 
and fertility rates [93-95]. 
Investigations from our lab have implicated specific microRNA as important factors in the female 
reproductive tract [97, 99].  Specifically we have identified 13 microRNA that are regulated by the surge 
of luteinizing hormone (LH) in mouse granulosa cells; 3 of which (microRNA-132, microRNA-212 and 
microRNA-21 (miR-21)) are upregulated [97].  Further studies showed that miR-21  functioned in 
granulosa cell viability and helped maintain optimal ovulation rates [99].  Because of its functional 
significance, this study sought to identify miR-21 direct targets within granulosa cells in an effort to 
elucidate the mechanism by which miR-21 carries out its anti-apoptotic and pro-ovulatory functions.        
MicroRNA directly target mRNA through binding to complementary sequences on the 3’UTR.  This 
binding event, which is mediated through the RNA Induced Silencing Complex causes repressed protein 
expression levels [47, 48, 206]. Subsequent to their initial discovery, it was believed that this 
mRNA/microRNA binding event repressed gene expression through some form of translational control 
[4, 5, 44, 45].  Studies from different labs pointed to different points at which microRNA mediated 
translational control took place, including inhibition of initiation of translation, repression after translation 
initiation and nascent polypeptide degradation [4, 5, 44, 45].  Under these different mechanisms of gene 
regulation, it was believed that steady-state mRNA levels were not affected by microRNA [4, 5, 44, 45].  
It was hypothesized that, unlike plant microRNA which typically have perfect complementarity between 
the microRNA and mRNA [207], the imperfect base pairing that takes place between mRNA and 
microRNA in mammalian systems, does not lead to mRNA degradation.   
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More recent research, however, has disputed this idea.  Several studies have shown that microRNA can 
regulate large number of target mRNAs and that for many highly repressed targets, steady-state mRNA 
changes is the major component of gene regulation [14, 40, 41].  In addition one study reported that many 
of the mRNA regulated by microRNA contain binding sites in their 3’UTR that are complementary to the 
microRNA [42].  This latter finding suggests that mRNA destabilization may occur in mRNA that are 
directly targeted by microRNA. 
Due to its functional importance in the ovary, this study sought to identify miR-21 direct targets in 
granulosa cells through analyzing its effects on steady-state mRNA levels.  To identify these targets, 
microarrays were used to determine differential gene expression at 2, 4, and 8 hours following 
knockdown of miR-21 in granulosa cells.  Loss of miR-21 caused widespread changes in gene expression 
and bioinformatics analysis showed that many of the dysregulated genes had putative miR-21 binding 
sites in their 3’UTR implicating them as potential miR-21 direct targets.  Potential miR-21 direct targets 
in granulosa cells were evaluated using gene specific 3’UTRs linked to a luciferase reporter; three genes 
intestinal transcription factor (ISX), apilipoprotein B mRNA editing enzyme catalytic polypeptide 3 
(apobec3), and ubiquitin specific protease 30 (USP30) were confirmed direct targets.  Previous research 
has implicated ISX, Apobec3 and USP30 in lipid absorption in the intestine, restricting retrovirus 
mobility and maintenance of mitochondrial morphology, respectively.  Through directly targeting these 
genes, miR-21 may be regulating these processes in granulosa cells.   
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3.  Experimental Procedures 
Granulosa cell isolation and Culture 
Immature CF-1 female mice were sacrificed at 25 days of age using cervical dislocation in accordance 
with the protocol for animal sacrifice approved by the Internal Care and Use Committee at the University 
of Kansas Medical Center.  After sacrifice ovaries were removed immediately and placed in M199 
collection media (Sigma-Adrich, St. Louis, MO.) supplemented with 10mM HEPES and 0.2% BSA.  
Media was removed and replaced with M199 media supplemented with 0 .5M sucrose and 1.8mM 
EGTA.  Ovaries were incubated in media in a 37
o
C water bath for 15 minutes.  After incubation, ovaries 
were washed with M199 media three times.  Antral follicles were poked with 28 gauge insulin needles 
(Becton Dickinson, Franklin Lakes, NJ.) to release granulosa cells.  Cells were transferred to a 15ml 
conical tube and spun for 15 minutes at 800 rcf.  Cells were plated in 6 well plates that had been 
previously coated with fibronectin at a density of 250,000 per well in DMEM F-12 HAM (Sigma-Aldrich, 
St. Louis, MO.) supplemented with 10% FBS and 1% gentamicin.  Cells were incubated at 37
o
C, 5% CO2 
for 48 hours prior to transfection.   
Array Analysis 
After 48 hours in culture, granulosa cells were transfected with a locked nucleic acid specific for miR-21 
(LNA-21) (5’-+T+C+AGTCTGATAA+G+C+TA-3’) (Integrated DNA technologies, Coralville, IA.) or 
with a non-specific locked nucleic acid (LNA-NS)(5’+C+G+TCAGTATGCG+A+A+TC-3’)at a 
concentration of 5uM per well of a 6-well plate.  At 2, 4 and 8 hours post transfection, cells were 
harvested and quality of RNA was assessed using Agilent Bioanalyzer 2001 (Agilent Incorp., Palo Alto, 
CA.).  RNA was biotin labeled and fragmented according to Affymetrix protocols.   Fragmented RNA 
from each sample was hybridized to the Affymetrix 430E 2.0 arrays (n=3, for each time point) and 
scanned using the gene array scanner (Affymetrix, Santa Clara, CA.).  For each chip analyzed the mean 
fluorescence was averaged to baseline fluorescence. 
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Cloning of ISX into siCHECK-2 (Promega) plasmid 
The entire 3’UTR (Genome Browser) of Apobec3, CASR, CCNE1, CD151, ISX, LGALS, TIAM1, 
USP30 and WDR5 was separately amplified from mouse genomic DNA (Table VI-5).  Thirty-five cycles 
of amplification was performed using denaturing, annealing and extension conditions at 94
o
C, 55
o
C and 
68
o
C degrees, respectively.  Primers were designed such that when the 3’UTRs of Apobec 3, CASR, 
CCNE1, CD151, LGALS and TIAM1 were amplified each fragment contained a 5’ XhoI restriction site 
and a 3’ NotI restriction site (Supplmental Table 3).  USP30 and ISX contained 5’ SgfI and 3’ NotI 
restriction sites after amplification (Supplmental Table 3).  After amplification each DNA fragment was 
cut with restriction enzymes that matched the sites on the amplified fragments (New England Biolabs, 
Ipswich, MA.) at 37
o
C overnight using appropriate buffer.  Subsequently cut fragment was cloned into 
siCHECK-2 (Promega, Madison, WI.) (Vector was cut with same enzymes and under the same conditions 
as that of the fragment being inserted) using T4 DNA ligase enzyme and appropriate buffer (New 
England Biolabs, Ipswich, MA.) at 4
o
C overnight.   Plasmid with inserted construct was transformed into 
DH5α cells (Life Technologies, Carlsbad, CA.) using a standard transformation protocol and grown on 
LB ampicillin plates.   After overnight growth at 37
o
C, colonies were lifted and grown overnight at 37
o
C 
in LB ampicillin media.  DNA was isolated and correct clones were confirmed through sequencing.  
Luciferase analysis 
After 48 hours in culture, granulosa cells were co-transfected with siCHECK-2 plasmid containing the 
3’UTR of one of the genes along with pre-microRNA-21 (pre-miR-21) (an immature form of miR-21 that 
gets processed into the mature form using the cell machinery) (Life Technologies, Carlsbad, CA.) or pre-
miR-NS ( non-specific pre-miR used as a control).  Co-transfections were done using lipofectamine 2000 
(Life Technologies, Carslbad, CA.) per the manufacturer’s protocol.  DNA was transfected at a 
concentration of 10ng and pre-miRs were transfected at 5uM, per well of a 6-well plate.  24 hours after 
transfection cells were harvested and lysed using passive lysis buffer (Promega, Madison, WI.).  Lysates 
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were prepared for luciferase using the dual luciferase reporter assay system (Promega, Madison, WI.) per 
the manufacturers’ protocol.  Luciferase assays were performed on the Berthold Lumat LB 9501 
Luminometer (Wallac, Gaithersburg, MD.).  .    
Statistical analysis 
 
Student’s T-test was used to determine if there were statistically different firefly/renilla expression ratio 
between the pre-miR-NS and pre-miR-21 treated cells.  Statistical significance was set at p<0.05.  For 
each luciferase assay performed 3 biological replicates were used (n=3).  Each biological replicate 
contained 3 technical replicates, which were averaged and subsequently used in the statistical analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
4.  Results and Tables/Figures 
Across all three time points there were a total of 1,950 genes that were dysregulated due to LNA-21 
treatment compared to LNA-NS treated cells (Table VI-1).  At 2 hour there were 148 and 110 upregulated 
and inhibited, respectively (total, 258); at 4 hour there were 759 and 321 upregulated and inhibited (total, 
1080), respectively; at 8 hour there were 372 and 240 upregulated and inhibited, respectively (total, 612) 
(Table VI-1).  There were 40 genes that were up or down regulated at multiple time points at least 1.2 fold 
due to LNA treatment.  Loss of miR-21 in granulosa cells failed to cause any gene to exhibit a more than 
3-fold change and only 9 genes had a greater than 2-fold change.  Together these data show that miR-21 
does modestly affect a vast number of genes at the mRNA level in granulosa cells.  
In order to identify potential miR-21 direct targets, genes upregulated more than 1.2 fold were analyzed 
using the bioinformatics algorithms microR, miRanda, PicTar, PITA and TargetScan to determine if their 
3’UTR had potential miR-21 binding sites.  Results of this analysis showed that there were 54 genes at 
2hr, 201 genes at 4hr and 102 genes at 8hr (357 total) contained putative miR-21 binding sites in their 
3’utr (Table VI-2) (Table VI-4).     
Due to miR-21’s previously defined role in apoptosis in granulosa cells, we selected 9 of the 263 for 
further investigation These genes had previously reported roles in apoptosis, carcinogenesis and cell 
differentiation (Table VI-3).  Genes chosen included apolipoprotein B mRNA editing enzyme catalytic 
polypeptide 3 (Apobec3), calcium-sensing receptor (CASR), cyclin E1 (CCNE1), tetraspanin CD151 
(CD151), intestinal-specific homeobox (ISX), galectin 3 (LGALS), T-lymphoma invasion and metastasis 
inducing protein (TIAM1), ubiquitin-specific protease 30 (USP30) and WD40-repeat protein (WDR5) 
(Table VI-3). 
To evaluate the ability of miR-21 these gene’s 3’UTR in granulosa cells, we carried out 3’UTR luciferase 
reporter assays.  3’UTR luciferase reporters for CASR, CCNE1, CD151, LGALS, TIAM1 and WDR5 
failed to exhibit differential activity following 24 hours of increased miR-21 expression induced by the 
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co-transfection of pre-miR-21 (Figure VI-1).  Three of the 9 gene’s 3’UTRs, however, did elicit a 
significant decrease in the ratio of the renilla/firefly activity following overexpression of miR-21.  These 
genes included ISX, USP30 and Apobec3, which exhibited a 30.1%, 27.8% and 24.3% reduction in the 
renilla/firefly ratio, respectively, when miR-21 was overexpressed compared to the control treated cells 
(n=3, p<0.05) (Figure VI-1).   
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Table VI-1.  Array summary of 1,950 genes that are differentially regulated in granulosa cells ≥1.2 
across all three time points following loss of miR-21 compared to control treated cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Table VI-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time Point 2hr 4hr 8hr 
Up-regulated genes after LNA-21 148 759 372 
Down-regulated genes after LNA-21 110 321 240 
Total 258 1080 612 
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Table VI-2.  Summary of 357 genes across all three time points that were incuded ≥1.2 fold and 
contained at least one potential miR-21 binding site in their 3’utr per at least one algorithm (microT, 
miRanda, PicTar, PITA and TargetScan).   
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Table VI-2 
Time Point 2hr 4hr 8hr 
Up-regulated after LNA-21 with potential 
miR-21 binding site 54 201 102 
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Table VI-3.  Characteristics of 9 selected upregulated genes in granulosa cells that are being tested for 
direct miR-21 binding using 3’UTR luciferase reporters. Genes were chosen due to their roles of 
apoptosis, carcinogenesis and cell differentiation identified in other tissues. 
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Table VI-3 
gene name gene 
symbol 
array time 
point/fold change function 
Apolipoprotein B mRNA 
editing enzyme catalytic 
polypeptide 3 
Apobec3 4hr (1.40 fold 
increase) 
restricts mobility of retroviruses and 
inhibits mircoRNA mediated decay of 
mRNA 
Calcium-sensing receptor CASR 8hr (1.24 fold 
increase) GPCR important in calcium homeostasis 
Cyclin E1 CCNE1 8hr (1.26 fold 
increase) 
important for cell cycle progression and 
often overexpressed in cancer cells 
Tetraspanin CD151 CD151 4hr (1.21 fold 
increase) 
interacts with laminin to promote cell 
adhesion, important for carcinoma cell 
motility 
Intestinal-specific 
homeobox ISX 
8hr (1.27 fold 
increase) 
plays a role in intestinal  differentiation 
and the gastric carcinogenic pathway 
galectin 3 LGALS 4hr (1.21 fold 
increase) promotes T-cell growth and apoptosis 
T-lymphoma invasion and 
metastasis inducing 
protein 
TIAM1 4hr (1.30 fold 
increase) 
regulates cytoskeletal organization, 
overexpressed in many tumor cell lines 
Ubiquitin-specific protease 
30  USP30 
8hr (1.20  fold 
increase) functions in mitochondrial morphology 
WD40-repeat protein WDR5 
4hr (1.33 fold 
increase) 
involved in cell cycle, RNA splicing, 
transcription and apoptosis 
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Figure VI-1.  Effect of miR-21 overexpression on 3’UTR luciferase reporter activity for select 
upregulated genes.  Granulosa cells were co-transfected with individual gene 3’UTR siCHECK-2 vector 
and either the pre-miR-NS or pre-miR-21 oligonucleotides. Graphs show mean +/- SEM of the 
renilla/firefly ratio expression values after each treatment (n=3).  *Means +/- SEM are statistically 
different (p<.05). 
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Figure VI-1 
      
                
 
   
 
 
 
 
 
 
* * * 
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5. Discussion 
This investigation shows that blockage of miR-21 in granulosa cells leads to widespread dysregulation of 
numerous mRNA.  A significant percentage of these genes were shown to be potential miR-21 direct 
targets according to bioinformatic algorithms.  Luciferase reporter analysis of a select number of these 
miR-21 direct targets implicated 3 as miR-21 direct targets in granulosa cells; USP30, Apobec3 and ISX. 
Each of these genes, have previously been shown to have functions that may have significance for 
granulosa cells and the ovary.  Ubiquitin-specific protease 30 (USP30) is a gene that is embedded in the 
mitochondrial membrane that plays a role in the maintenance of mitochondrial morphology.  Depletion of 
USP30 causes mitochondria to become interconnected and take on an elongated shape [208].  Previous 
studies have shown that there are elaborate microtubular systems in granulosa cells when compared to 
other cell types and that morphological changes in the mitochondria have been linked to deviations in 
steroid hormone output in the ovary [209-211].  It is feasible that USP30 is under miR-21 direct 
regulation to induce the necessary mitochondrial morphological changes in granulosa cells to properly 
regulate steroidogenesis.  Northern blot analysis has also shown that USP30 has high expression in the 
gonads when compared to other tissues types further suggesting that this gene may have functional 
significance in the ovary [208].    
Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3’s (Apobec3) primary functional role is 
to confer innate immunity to a wide range of exogenous retroviruses.  It carries out this function, in part, 
through the regulation of immune markers [212].  It is known that the LH surge causes induction of 
chemokines MCP-1 and IL-8 and that macrophages, neutrophilic granulocytes, and T-lymphocytes are 
present in the ovarian cells, including granulosa cells, at ovulation.  It has been hypothesized that these 
immune markers may be functioning in tissue remodeling, which occurs during ovulation [213, 214].  
MiR-21, which our lab has shown to regulate ovulation, may be directly targeting Apobec3 in an effort to 
modulate functionally important immunologic markers.   
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Intestinal-specific homeobox (ISX) is a homeobox transcription factor that regulates vitamin A 
metabolism and SRB1 expression levels [215].    Vitamin A is known to function in the female germline 
and female reproduction while SRB1 is critical for cholesterol uptake and steroidogenesis in the ovary.  
MiR-21 may be targeting ISX to regulate these functions in the ovary.  SRB1 is also known to be under 
LH regulation in the ovary [216, 217].  Our lab has previously shown that miR-21 is also under LH 
control in the ovary.  Together these findings suggest the possibility that the mechanism of SRB1 
hormonal control is via miR-21’s directly targeting ISX.    
Along with identifying miR-21 direct targets, it is also significant that this study failed to implicate Tiam1 
as a miR-21 direct target.  Tiam1 was induced 1.3 fold four hours after miR-21 inhibition and 
bioinformatics analysis identified a potential miR-21 binding site in its 3’UTR.  Most importantly, Tiam1 
has been previously identified as a miR-21 direct target in colon carcinoma cells [218].  While our array 
and bioinformatics analysis suggested Tiam1 may be a miR-21 direct target, luciferase analysis failed to 
show that miR-21 could regulate its 3’UTR.  This lack of ability to identify the same gene as a microRNA 
direct target across two different cell types finds significant support in the literature.  Specifically for 
miR-21, while some of its direct targets have been identified in multiple cancer cell lines, the majority 
have been unique to the cell or tissue type under investigation [126, 129, 130, 132-134, 137, 140, 218].  
The lack of ability to identify Tiam1 as a miR-21 direct target in granulosa cells, whether that means it is 
not an actual target in this cell type or just that this study was unable to identify it as such, is consistent 
with these previous studies.      
Findings from this study are consistent with previous reports that have shown that microRNA do have 
moderate, yet, statistically effects on steady-state mRNA levels and that microRNA direct targets are 
regulated at the mRNA level [14, 40, 41].  And while this study identified 3 novel miR-21 direct targets, 6 
of the targets examined could not be verified as miR-21 direct targets.  Luciferase analysis would need to 
be performed on the remaining 378 genes that were induced following loss of miR-21 and had potential 
miR-21 binding sites in their 3’UTR, to determine if they were bona fide miR-21 direct targets.  
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This study is the first to implicate microRNA direct target in granulosa cells.  It is also the first to identify 
miR-21 direct targets in a physiological system.  Further studies will be needed to determine if the 3 
currently identified genes are functionally important targets in the context of granulosa cells and/or 
ovarian biology.   
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6.  Supplemental Data 
Table VI-4.  List of all genes across all three time points dysregulated ≥ 1.2 fold following inhibition of 
miR-21 that contain potential miR-21 binding sites in their 3’UTR.  Table contains gene symbol, gene 
name, fold change and p-value. 
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Table VI-4 
Gene 
Symbol Gene Name 
Fold 
Change P-value 
Array 
Time 
Point 
KCNA1 potassium voltage-gated channel; shaker-related subfamily; member 1 1.24066 0.0381492 8hr 
YAP1 yes-associated protein 1 1.21551 0.018231 4hr 
MAP2K3 mitogen-activated protein kinase kinase 3 1.22371 0.0308353 8hr 
2310035C23RIK RIKEN cDNA 2310035C23 gene 1.2748 0.0382897 8hr 
RALGPS1 Ral GEF with PH domain and SH3 binding motif 1 1.25791 0.0467209 8hr 
STX2 syntaxin 2 1.23431 0.034218 8hr 
CASR calcium-sensing receptor 1.23596 0.0237921 8hr 
CNNM4 cyclin M4 1.2244 0.0234587 8hr 
ISX intestine specific homeobox 1.26309 0.0284002 8hr 
ATP8A1 ATPase; aminophospholipid transporter (APLT); class I; type 8A; member 1 1.24654 0.0369261 8hr 
PSD2 pleckstrin and Sec7 domain containing 2 1.2342 0.0287654 8hr 
CD244 CD244 natural killer cell receptor 2B4 1.2094 0.0378144 8hr 
USP47 ubiquitin specific peptidase 47 1.23215 0.0353436 2hr 
WDR5 WD repeat domain 54 1.39324 0.0331789 4hr 
MSX1 homeobox; msh-like 1 1.26411 0.0262056 4hr 
RUNX3 runt related transcription factor 3 1.19886 0.0298386 4hr 
PDE6G phosphodiesterase 6G; cGMP-specific; rod; gamma 1.2723 0.0302749 4hr 
TOM1L2 target of myb1-like 2 (chicken) 1.22915 0.00379625 4hr 
ATCAY ataxia; cerebellar; Cayman type homolog (human) 1.10285 0.00419113 4hr 
DNAJC16 DnaJ (Hsp40) homolog; subfamily C; member 16 1.28176 0.0219148 4hr 
SPIN1 similar to Spindlin 1 /// spindlin 1 1.39803 0.044587 4hr 
PCDH12 protocadherin 12 1.27659 0.0439822 4hr 
CNR1 cannabinoid receptor 1 (brain) 1.20281 0.0152991 4hr 
TIAM1 T-cell lymphoma invasion and metastasis 1 1.29708 0.0395434 4hr 
LZTFL1 leucine zipper transcription factor-like 1 1.24237 0.0203538 4hr 
LIG3 ligase III; DNA; ATP-dependent 1.25771 0.046681 4hr 
TSSK2 testis-specific serine kinase 2 1.29503 0.030274 4hr 
MTHFR 5;10-methylenetetrahydrofolate reductase 1.20036 0.0308539 2hr 
4933439F18RIK Hypothetical protein (ORF1) 1.34886 0.00500596 2hr 
NEK6 NIMA (never in mitosis gene a)-related expressed kinase 6 1.24016 0.0386376 8hr 
RNF144A ring finger protein 144A 1.33035 0.00712759 8hr 
DMRTC1A DMRT-like family C1a 1.22113 0.0330858 8hr 
SEL1L deoxyribonuclease 1-like 2 /// similar to Dnase1l2 protein 1.45314 0.0470193 8hr 
TPCN1 two pore channel 1 1.38189 0.00464223 8hr 
KCND3 potassium voltage-gated channel; Shal-related family; member 3 1.24132 0.0364306 8hr 
EPHB2 Eph receptor B2 1.20284 0.0442559 8hr 
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LOC100044065 
/// ODZ1 
similar to odd Oz/ten-m homolog 1 (Drosophila) /// odd Oz/ten-m 
homolog 1 (Drosophila) 1.44758 0.0263521 8hr 
GALNT13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 1.32545 0.0283911 8hr 
MSMB beta-microseminoprotein 1.36798 0.0351251 8hr 
BCL7A B-cell CLL/lymphoma 7A 1.22852 0.00949237 8hr 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.24707 0.011334 8hr 
DUSP8 dual specificity phosphatase 8 1.41019 0.00814115 8hr 
PPP1R10 
predicted gene; 100039405 /// similar to protein phosphatase 1; 
regulatory subunit 10 /// protein phosphatase 1; regulatory subunit 10 1.33757 0.0459527 8hr 
H1FOO H1 histone family; member O; oocyte-specific 1.18956 0.0397726 4hr 
WDR85 WD repeat domain 85 1.43561 0.0486218 4hr 
2610110G12RIK RIKEN cDNA 2610110G12 gene 1.37657 0.0232366 4hr 
CGREF1 cell growth regulator with EF hand domain 1 1.40623 0.0349903 4hr 
GPR88 G-protein coupled receptor 88 1.23105 0.0290101 4hr 
SSTR5 somatostatin receptor 5 1.32819 0.0387656 4hr 
TTC14 tetratricopeptide repeat domain 14 1.21715 0.0246102 4hr 
BSDC1 BSD domain containing 1 1.34953 0.0363251 4hr 
IKBKG inhibitor of kappaB kinase gamma 1.29765 0.0407163 4hr 
1700052N19RI
K RIKEN cDNA 1700052N19 gene 1.21604 0.0283057 4hr 
TIMP2 tissue inhibitor of metalloproteinase 2 1.22514 
0.00031217
6 4hr 
BC053393 cDNA sequence BC053393 1.30954 0.00758184 4hr 
GAL3ST2 galactose-3-O-sulfotransferase 2 1.20966 0.0494251 4hr 
STXBP1 syntaxin binding protein 1 1.3435 0.0310694 4hr 
BMPR1B bone morphogenetic protein receptor; type 1B 1.20182 0.0216408 4hr 
SATB1 
Special AT-rich sequence binding protein 1; mRNA (cDNA clone 
MGC:18461 IMAGE:4164993) 1.20434 0.0355016 4hr 
LCP2 lymphocyte cytosolic protein 2 1.28997 0.023994 4hr 
CLEC4A2 C-type lectin domain family 4; member a2 1.40725 0.0343368 4hr 
NFIC nuclear factor I/C 1.33857 0.0247482 4hr 
FANCM Fanconi anemia; complementation group M 1.30273 0.0218963 2hr 
FGD4 FYVE; RhoGEF and PH domain containing 4 1.27461 0.010757 2hr 
RAB40B Rab40b; member RAS oncogene family 1.22058 0.0225316 2hr 
STAT1 signal transducer and activator of transcription 1 1.24077 0.0139625 2hr 
TNS4 tensin 4 1.21525 0.00546456 2hr 
SLC5A7 solute carrier family 5 (choline transporter); member 7 1.35935 0.0276498 2hr 
MC1R melanocortin 1 receptor 1.24041 0.0135792 8hr 
KLRB1C killer cell lectin-like receptor subfamily B member 1C 1.30395 0.0477138 8hr 
AK3L1 adenylate kinase 3-like 1 /// similar to adenylate kinase 4 1.31706 0.0401146 8hr 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 1.19567 0.0294399 8hr 
LOC100046704 
/// NRAS similar to neuroblastoma ras oncogene /// neuroblastoma ras oncogene 1.22974 0.0428806 8hr 
FBLN1 fibulin 1 1.31901 0.0485345 8hr 
NUTF2 nuclear transport factor 2 1.29939 0.0176036 8hr 
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COPG coatomer protein complex; subunit gamma 1.27054 0.0212557 8hr 
SYS1 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) 1.2427 0.0289906 8hr 
SETMAR SET domain and mariner transposase fusion gene 1.20264 0.0325313 8hr 
ANAPC11 
Anaphase promoting complex subunit 11; mRNA (cDNA clone MGC:35764 
IMAGE:5356010) 1.27847 0.0318457 8hr 
NRP neural regeneration protein 1.38904 0.0263308 8hr 
SLC10A7 solute carrier family 10 (sodium/bile acid cotransporter family); member 7 1.33827 0.0411596 8hr 
NFIX heat shock transcription factor family member 5 1.29147 0.0230708 8hr 
2210020M01RI
K RIKEN cDNA 2210020M01 gene 1.21661 0.0173907 8hr 
UCP2 
Uncoupling protein 2 (mitochondrial; proton carrier); mRNA (cDNA clone 
MGC:13955 IMAGE:4205625) 1.3288 0.00108009 8hr 
CAP2 CAP; adenylate cyclase-associated protein; 2 (yeast) 1.31103 0.0448868 8hr 
4833439L19RIK RIKEN cDNA 4833439L19 gene 1.22641 0.0294885 8hr 
KCNIP3 Kv channel interacting protein 3; calsenilin 1.31158 0.0268974 8hr 
SH3GL3 SH3-domain GRB2-like 3 1.21961 0.00541832 8hr 
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1.25029 0.00143075 8hr 
SYS1 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) 1.2427 0.0289906 8hr 
NPCD /// 
NPTXR neuronal pentraxin with chromo domain /// neuronal pentraxin receptor 1.2506 0.0418691 8hr 
FOXS1 forkhead box S1 1.34367 0.0314605 8hr 
ETV1 ets variant gene 1 1.32093 0.0459477 8hr 
RAB36 RAB36; member RAS oncogene family 1.25816 0.0348 8hr 
MAPK12 mitogen-activated protein kinase 12 1.2472 0.00294082 8hr 
2810046L04RIK RIKEN cDNA 2810046L04 gene 1.23751 0.00227067 8hr 
NEUROG1 neurogenin 1 1.20242 0.0116106 8hr 
HSF5 heat shock transcription factor family member 5 1.29147 0.0230708 8hr 
RECQL RecQ protein-like 1.19606 0.0401784 8hr 
GNAS 
GNAS (guanine nucleotide binding protein; alpha stimulating) complex 
locus 1.20489 0.0259956 8hr 
4930579E17RIK RIKEN cDNA 4930579E17 gene 1.19629 0.0332697 8hr 
SCN3B sodium channel; voltage-gated; type III; beta 1.20291 0.0124925 8hr 
1700065D16RIK RIKEN cDNA 1700065D16 gene 1.20812 0.0120007 8hr 
CD151 CD151 antigen 1.20037 0.0465499 4hr 
LGALS3 lectin; galactose binding; soluble 3 1.2083 0.0241608 4hr 
RAD23A RAD23a homolog (S. cerevisiae) 1.18939 0.0048281 4hr 
DRG2 developmentally regulated GTP binding protein 2 1.37148 0.0459712 4hr 
TMEM206 transmembrane protein 206 1.2573 0.0453215 4hr 
APOBEC3 apolipoprotein B mRNA editing enzyme; catalytic polypeptide 3 1.38165 0.0372923 4hr 
DZIP3 DAZ interacting protein 3; zinc finger 1.30721 0.00202659 4hr 
TBL1XR1 transducin (beta)-like 1X-linked receptor 1 1.23375 0.0409055 4hr 
SOCS2 suppressor of cytokine signaling 2 1.27435 0.0284393 4hr 
UBN2 ubinuclein 2 1.35502 0.0335606 4hr 
ZFP444 zinc finger protein 444 1.46436 0.00163213 4hr 
TRAPPC6A trafficking protein particle complex 6A 1.63855 0.00781959 4hr 
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ANTXR1 anthrax toxin receptor 1 1.3414 0.0483811 4hr 
ENTPD7 ectonucleoside triphosphate diphosphohydrolase 7 1.22614 0.0209234 4hr 
ARVCF armadillo repeat gene deleted in velo-cardio-facial syndrome 1.30458 0.0398695 4hr 
GPR44 G protein-coupled receptor 44 1.36093 0.0276785 4hr 
KCNJ6 potassium inwardly-rectifying channel; subfamily J; member 6 1.25993 0.044754 4hr 
KCNF1 potassium voltage-gated channel; subfamily F; member 1 1.33999 0.0152435 4hr 
N28178 expressed sequence N28178 1.31287 0.029663 4hr 
IKBKB inhibitor of kappaB kinase beta 1.21493 0.0130966 4hr 
MYO19 myosin XIX 1.24208 0.0132445 4hr 
CASP9 caspase 9 1.23768 0.0322464 4hr 
MED20 /// 
USP49 mediator complex subunit 20 /// ubiquitin specific peptidase 49 1.28398 0.00711972 4hr 
JAKMIP1 janus kinase and microtubule interacting protein 1 1.26088 0.0495906 4hr 
SH2D2A SH2 domain protein 2A 1.22417 0.0427331 4hr 
CREB3L4 cAMP responsive element binding protein 3-like 4 1.52371 0.0250845 4hr 
SYS1 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) 1.20698 0.0258872 4hr 
RNF38 ring finger protein 38 1.3763 0.0320749 4hr 
EMP2 epithelial membrane protein 2 1.29212 0.0188186 4hr 
PLDN pallidin 1.36334 0.00265435 4hr 
CD93 CD93 antigen 1.2251 0.0316378 4hr 
KIF5B Kinesin family member 5B (Kif5b); mRNA 1.16378 0.0450234 4hr 
4732429D16RIK RIKEN cDNA 4732429D16 gene 1.2312 0.021766 4hr 
BC020535 cDNA sequence BC020535 1.21566 0.0318979 4hr 
ADAM28 a disintegrin and metallopeptidase domain 28 1.28904 0.00947245 4hr 
S1PR3 sphingosine-1-phosphate receptor 3 1.38107 0.00288585 4hr 
MARVELD3 MARVEL (membrane-associating) domain containing 3 1.36351 0.00394438 4hr 
IQGAP1 IQ motif containing GTPase activating protein 1 1.27375 0.020949 4hr 
GIP gastric inhibitory polypeptide 1.28366 0.0436636 4hr 
CSRP3 cysteine and glycine-rich protein 3 1.24109 0.0393396 4hr 
ATAD4 ATPase family; AAA domain containing 4 1.34773 0.0241957 4hr 
TNFRSF11A tumor necrosis factor receptor superfamily; member 11a 1.23895 0.00944203 4hr 
AIM1L absent in melanoma 1-like 1.27806 0.0471632 4hr 
LIPC lipase; hepatic 1.29819 0.0289615 4hr 
MGAT3 mannoside acetylglucosaminyltransferase 3 1.2386 0.0171148 4hr 
NCOR1 nuclear receptor co-repressor 1 1.32519 0.0267844 4hr 
TBC1D5 TBC1 domain family; member 5 1.22162 0.041967 4hr 
2810055G20RIK RIKEN cDNA 2810055G20 gene 1.21382 0.00706424 4hr 
MPDZ multiple PDZ domain protein 1.29698 0.016222 4hr 
CABIN1 calcineurin binding protein 1 1.2898 0.0334187 4hr 
PDE4B 
Phosphodiesterase 4B; cAMP specific; mRNA (cDNA clone 
IMAGE:5354427) 1.32027 0.0340892 4hr 
CD93 CD93 antigen 1.2251 0.0316378 4hr 
DMRT3 Doublesex and mab-3 related transcription factor 3; mRNA (cDNA clone 1.20375 0.0434594 4hr 
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MGC:62407 IMAGE:6404988) 
ZHX1 zinc fingers and homeoboxes 1 1.22034 0.0292768 4hr 
EBF2 early B-cell factor 2 1.21205 0.00465592 4hr 
B3GALNT2 
UDP-GalNAc:betaGlcNAc beta 1;3-galactosaminyltransferase; polypeptide 
2 1.21657 0.0192898 4hr 
5730507A09RIK RIKEN cDNA 5730507A09 gene 1.26531 0.00339387 4hr 
666661 /// 
APOL7C predicted gene; 666661 /// apolipoprotein L 7c 1.21095 0.0310188 4hr 
TMEM174 transmembrane protein 174 1.27495 0.015729 4hr 
CCDC53 coiled-coil domain containing 53 1.22417 0.0427331 4hr 
ADAMTS20 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif; 20 1.20064 0.00446484 4hr 
GGTA1 glycoprotein galactosyltransferase alpha 1; 3 1.47671 0.00175677 4hr 
ARHGEF9 CDC42 guanine nucleotide exchange factor (GEF) 9 1.20931 0.0358449 4hr 
RNF112 ring finger protein 112 1.20332 0.0289161 4hr 
C030003D03RI
K RIKEN cDNA C030003D03 gene 1.28318 0.043273 4hr 
CDC14A /// 
LOC100047731 
CDC14 cell division cycle 14 homolog A (S. cerevisiae) /// hypothetical 
protein LOC100047731 1.25287 0.0104667 4hr 
KCNB1 potassium voltage gated channel; Shab-related subfamily; member 1 1.24783 0.0264198 4hr 
TTC7 tetratricopeptide repeat domain 7 1.23992 0.0267143 4hr 
RHOH ras homolog gene family; member H 1.2172 0.021773 4hr 
SPSB4 splA/ryanodine receptor domain and SOCS box containing 4 1.3865 0.0470835 4hr 
RBM39 RNA binding motif protein 39 1.27075 0.0191579 2hr 
SLC7A11 
solute carrier family 7 (cationic amino acid transporter; y+ system); 
member 11 1.24219 0.0284351 2hr 
PXN paxillin 1.32417 0.0325027 2hr 
MAP3K9 mitogen-activated protein kinase kinase kinase 9 1.20477 0.0464807 2hr 
EDN3 endothelin 3 1.46281 0.00197219 2hr 
2810403A07RIK RIKEN cDNA 2810403A07 gene 1.3593 0.0251156 2hr 
LRCH3 
Leucine-rich repeats and calponin homology (CH) domain containing 3; 
mRNA (cDNA clone MGC:198849 IMAGE:9054814) 1.23988 0.00672849 2hr 
LIN54 lin-54 homolog (C. elegans) 1.23177 0.0364661 2hr 
4933403F05RIK RIKEN cDNA 4933403F05 gene 1.28247 0.0229778 2hr 
CUGBP2 CUG triplet repeat; RNA binding protein 2 1.29233 0.031647 2hr 
DGCR8 DiGeorge syndrome critical region gene 8 1.22353 0.0126917 2hr 
PAFAH1B1 
Platelet-activating factor acetylhydrolase; isoform 1b; beta1 subunit; 
mRNA (cDNA clone MGC:13913 IMAGE:4017963) 1.30018 0.0303562 2hr 
STEAP2 six transmembrane epithelial antigen of prostate 2 1.27721 0.0448114 2hr 
STXBP5L syntaxin binding protein 5-like 1.24979 0.0120968 2hr 
SEC22A SEC22 vesicle trafficking protein homologe A (S. cerevisiae) 1.22315 0.0179869 2hr 
GFOD1 glucose-fructose oxidoreductase domain containing 1 1.21 0.0104052 2hr 
SCARA5 scavenger receptor class A; member 5 (putative) 1.47773 0.0405373 2hr 
TMEM29 transmembrane protein 29 1.40516 0.00567558 8hr 
PHC2 polyhomeotic-like 2 (Drosophila) 1.27718 0.0446983 8hr 
GHR growth hormone receptor 1.22006 0.003078 8hr 
TTC28 tetratricopeptide repeat domain 28 1.23915 0.0218533 8hr 
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CCNY /// 
LOC100044842 cyclin Y /// similar to cyclin fold protein 1 1.20531 0.00794195 8hr 
CCNE1 cyclin E1 1.25368 0.015062 8hr 
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 1.21405 0.0434991 8hr 
FBXO21 F-box protein 21 1.2031 0.0340304 8hr 
MYLPF myosin light chain; phosphorylatable; fast skeletal muscle 1.27022 0.0271005 8hr 
MCM5 
minichromosome maintenance deficient 5; cell division cycle 46 (S. 
cerevisiae) 1.28009 0.0419356 8hr 
GRHL2 grainyhead-like 2 (Drosophila) 1.45489 0.04115 8hr 
LEPR leptin receptor 1.30297 0.0468672 8hr 
EG232599 
Predicted gene; EG232599; mRNA (cDNA clone MGC:156005 
IMAGE:40129691) 1.20106 0.0220952 8hr 
EDA ectodysplasin-A 1.23257 0.0104525 8hr 
LDLR low density lipoprotein receptor 1.41719 0.0391926 8hr 
ZFP651 zinc finger protein 651 1.20411 0.0289022 8hr 
CALR3 calreticulin 3 1.31668 0.0240547 8hr 
CENPA Centromere protein A; mRNA (cDNA clone MGC:13888 IMAGE:4018429) 1.3344 0.0445517 8hr 
USP30 ubiquitin specific peptidase 30 1.19824 0.0359382 8hr 
ZFP473 zinc finger protein 473 1.21327 0.0440109 8hr 
POU2F1 POU domain; class 2; transcription factor 1 1.21115 0.0119038 8hr 
ACOT12 acyl-CoA thioesterase 12 1.273 0.0254415 8hr 
COX4NB COX4 neighbor 1.21692 0.0360243 8hr 
GAS7 growth arrest specific 7 1.22461 0.049252 8hr 
NTSR1 neurotensin receptor 1 1.27018 0.020129 8hr 
SLC12A3 solute carrier family 12; member 3 1.32589 0.0447393 8hr 
C530008M17RI
K RIKEN cDNA C530008M17 gene 1.2 0.0414148 8hr 
VPRBP Vpr (HIV-1) binding protein 1.24638 0.0180449 8hr 
PVT1 plasmacytoma variant translocation 1 1.22902 0.0187565 8hr 
SYT17 synaptotagmin XVII 1.20427 0.013803 8hr 
GABRB3 gamma-aminobutyric acid (GABA) A receptor; subunit beta 3 1.22451 0.0307998 8hr 
ASAH2 N-acylsphingosine amidohydrolase 2 1.21031 0.0122681 8hr 
5730469M10RI
K RIKEN cDNA 5730469M10 gene 1.2101 0.00848491 8hr 
ELMO1 engulfment and cell motility 1; ced-12 homolog (C. elegans) 1.27493 0.0432414 8hr 
ENPEP glutamyl aminopeptidase 1.29743 0.0200332 8hr 
ACADL acyl-Coenzyme A dehydrogenase; long-chain 1.22746 0.0471311 8hr 
ZHX3 zinc fingers and homeoboxes 3 1.22889 0.00224961 8hr 
ROR1 receptor tyrosine kinase-like orphan receptor 1 1.20987 0.0119589 8hr 
DMC1 
DMC1 dosage suppressor of mck1 homolog; meiosis-specific homologous 
recombination (yeast) 1.2226 0.00382193 8hr 
SEC11A SEC11 homolog A (S. cerevisiae) 1.29546 0.0429056 8hr 
EOMES eomesodermin homolog (Xenopus laevis) 1.27725 0.0340839 8hr 
TRFR2 transferrin receptor 2 1.3379 0.00167195 4hr 
RANBP3 RAN binding protein 3 1.25067 0.049902 4hr 
RPS6KA4 ribosomal protein S6 kinase; polypeptide 4 1.31812 0.0492866 4hr 
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MTCH1 mitochondrial carrier homolog 1 (C. elegans) 1.56096 0.0210422 4hr 
CAPNS1 calpain; small subunit 1 1.40736 0.0385973 4hr 
ZDHHC3 zinc finger; DHHC domain containing 3 1.2741 0.0173486 4hr 
SNX12 sorting nexin 12 1.36964 0.0391086 4hr 
PIGU phosphatidylinositol glycan anchor biosynthesis; class U 1.20976 0.0379166 4hr 
SLC25A38 solute carrier family 25; member 38 1.31786 0.0276498 4hr 
SEC61A2 Sec61; alpha subunit 2 (S. cerevisiae) 1.23225 0.0447055 4hr 
TBC1D25 TBC1 domain family; member 25 1.23738 0.0310281 4hr 
WDR41 WD repeat domain 41 1.44788 0.0332607 4hr 
TOPBP1 topoisomerase (DNA) II binding protein 1 1.31327 0.0291106 4hr 
WDR41 WD repeat domain 41 1.25967 0.0273147 4hr 
BBS2 Bardet-Biedl syndrome 2 (human) 1.31536 0.016365 4hr 
2610021K21RIK RIKEN cDNA 2610021K21 gene 1.47377 
0.00038736
6 4hr 
HIF3A /// 
LOC641092 
hypoxia inducible factor 3; alpha subunit /// similar to hypoxia inducible 
factor 3; alpha subunit 1.41924 0.0295638 4hr 
CD160 CD160 antigen 1.29034 0.028802 4hr 
PLSCR4 phospholipid scramblase 4 1.2333 0.027773 4hr 
DLGAP1 discs; large (Drosophila) homolog-associated protein 1 1.2339 0.0283144 4hr 
AUH AU RNA binding protein/enoyl-coenzyme A hydratase 1.30963 0.0362311 4hr 
PDGFRB platelet derived growth factor receptor; beta polypeptide 1.31699 0.0329807 4hr 
PNPLA3 patatin-like phospholipase domain containing 3 1.47795 0.0238688 4hr 
KCNN3 
potassium intermediate/small conductance calcium-activated channel; 
subfamily N; member 3 1.34403 0.0465186 4hr 
HES5 hairy and enhancer of split 5 (Drosophila) 1.26451 0.04625 4hr 
KRT42 keratin 42 1.45001 0.0400028 4hr 
ZSWIM5 zinc finger; SWIM domain containing 5 1.44506 0.0403014 4hr 
TMPRSS2 transmembrane protease; serine 2 1.43772 0.0362834 4hr 
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 1.25466 0.033383 4hr 
6430548M08RI
K RIKEN cDNA 6430548M08 gene 1.24575 0.0438124 4hr 
EXOC6B exocyst complex component 6B 1.25007 0.0223597 4hr 
D2BWG1423E DNA segment; Chr 2; Brigham & Women's Genetics 1423 expressed 1.23145 0.00774136 4hr 
NCSTN nicastrin 1.26415 0.0152796 4hr 
SS18L1 synovial sarcoma translocation gene on chromosome 18-like 1 1.20556 0.0109055 4hr 
FAM19A5 family with sequence similarity 19; member A5 1.36901 0.00950877 4hr 
PNOC prepronociceptin 1.3553 0.0202261 4hr 
WDR22 WD repeat domain 22 1.47926 0.0109485 4hr 
HYAL1 /// NAT6 hyaluronoglucosaminidase 1 /// N-acetyltransferase 6 1.38476 
0.00071734
6 4hr 
MR1 major histocompatibility complex; class I-related 1.26252 0.00761025 4hr 
USP30 ubiquitin specific peptidase 30 1.23696 0.0380664 4hr 
CCDC84 coiled-coil domain containing 84 1.40305 0.01079 4hr 
SLC31A2 solute carrier family 31; member 2 1.2463 0.0154858 4hr 
SERHL serine hydrolase-like 1.50092 0.0461852 4hr 
49 
 
MYST1 MYST histone acetyltransferase 1 1.49239 0.0376414 4hr 
GM98 gene model 98; (NCBI) 1.25344 0.0379982 4hr 
TMEM181 /// 
TMEM181C-PS 
transmembrane protein 181 /// transmembrane protein 181C; 
pseudogene 1.36384 0.0483975 4hr 
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 1.28518 0.0397991 4hr 
MEG3 maternally expressed 3 1.21647 0.0486051 4hr 
FMOD fibromodulin 1.26686 0.0262299 4hr 
PER3 period homolog 3 (Drosophila) 1.31286 0.0204295 4hr 
OLFR78 olfactory receptor 78 1.32302 0.0336662 4hr 
DNAJB5 DnaJ (Hsp40) homolog; subfamily B; member 5 1.32879 0.0421913 4hr 
2900092E17RIK 
/// PRRT2 RIKEN cDNA 2900092E17 gene /// proline-rich transmembrane protein 2 1.26888 0.0323711 4hr 
CD80 CD80 antigen 1.23843 0.0116944 4hr 
ARID3B AT rich interactive domain 3B (BRIGHT-like) 1.21779 0.0023626 4hr 
CSF3R colony stimulating factor 3 receptor (granulocyte) 1.23806 0.0419324 4hr 
HOXC13 homeo box C13 1.21624 0.0135379 4hr 
ACTA2 actin; alpha 2; smooth muscle; aorta 1.24188 
0.00083019
3 4hr 
KBTBD11 
Kelch repeat and BTB (POZ) domain containing 11; mRNA (cDNA clone 
MGC:90804 IMAGE:6852896) 1.28919 0.0255294 4hr 
P2RX3 purinergic receptor P2X; ligand-gated ion channel; 3 1.2049 0.00986529 4hr 
ADH6A alcohol dehydrogenase 6A (class V) 1.23987 0.0156428 4hr 
PHACTR3 phosphatase and actin regulator 3 1.42477 0.0412105 4hr 
4930452B06RIK RIKEN cDNA 4930452B06 gene 1.26624 
0.00035576
5 4hr 
ERCC8 
excision repaiross-complementing rodent repair deficiency; 
complementation group 8 1.26181 0.0030426 4hr 
LEPR leptin receptor 1.20744 0.0468575 4hr 
DDO D-aspartate oxidase 1.24317 0.0494806 4hr 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 1.22279 0.035983 4hr 
LIMCH1 LIM and calponin homology domains 1 1.2013 0.0141982 4hr 
CALCOCO2 calcium binding and coiled-coil domain 2 1.22109 0.0309509 4hr 
ITGB2L integrin beta 2-like 1.21015 0.0467201 4hr 
ELK4 ELK4; member of ETS oncogene family 1.22889 0.01276 4hr 
APOL11B apolipoprotein L 11b 1.20907 0.0103135 4hr 
RBM24 RNA binding motif protein 24 1.27861 0.0464648 4hr 
ANGPTL3 angiopoietin-like 3 1.2457 0.043562 4hr 
SHISA2 shisa homolog 2 (Xenopus laevis) 1.25564 0.0131316 4hr 
1810034E14RIK RIKEN cDNA 1810034E14 gene 1.2366 0.020692 4hr 
LGR5 leucine rich repeat containing G protein coupled receptor 5 1.20803 0.0226626 4hr 
CPLX4 complexin 4 1.20601 0.0345655 4hr 
DRD1A dopamine receptor D1A 1.29043 0.00856576 4hr 
SYPL2 synaptophysin-like 2 1.21802 0.0136843 4hr 
FRY PREDICTED: Mus musculus furry homolog (Drosophila) (Fry); mRNA 1.2278 0.0406877 4hr 
UTY ubiquitously transcribed tetratricopeptide repeat gene; Y chromosome 1.2168 0.0395481 4hr 
CACNA2D4 calcium channel; voltage-dependent; alpha 2/delta subunit 4 1.31956 0.0211761 4hr 
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EVI2B ecotropic viral integration site 2b 1.24042 0.00319271 4hr 
TLE4 ecotropic viral integration site 2b 1.24042 0.00319271 4hr 
NRXN3 neurexin III 1.20262 0.0491121 4hr 
DYM dymeclin 1.23266 0.02255 4hr 
B130034C11RIK RIKEN cDNA B130034C11 gene 1.20487 0.00159592 4hr 
RPGRIP1 retinitis pigmentosa GTPase regulator interacting protein 1 1.1985 0.00545045 4hr 
TBC1D14 TBC1 domain family; member 14 1.21957 0.0248394 4hr 
FAM179B family with sequence similarity 179; member B 1.36362 0.0442118 4hr 
GABRA1 gamma-aminobutyric acid (GABA) A receptor; subunit alpha 1 1.37592 0.0386429 4hr 
PRAMEF12 PRAME family member 12 1.20598 0.037564 4hr 
AU018091 expressed sequence AU018091 1.32694 0.0306449 4hr 
PIRA2 paired-Ig-like receptor A2 1.34356 0.01633 4hr 
LCOR ligand dependent nuclear receptor corepressor 1.25776 0.0273233 4hr 
THUMPD3 THUMP domain containing 3 1.30399 0.0453354 4hr 
NCAPH2 non-SMC condensin II complex; subunit H2 1.28319 0.00144291 2hr 
ELOVL1 
elongation of very long chain fatty acids (FEN1/Elo2; SUR4/Elo3; yeast)-like 
1 1.2169 0.0283276 2hr 
2310079F23RIK RIKEN cDNA 2310079F23 gene 1.22044 0.0254718 2hr 
PITPNM2 phosphatidylinositol transfer protein; membrane-associated 2 1.24444 0.0193494 2hr 
CALD1 caldesmon 1 1.32562 0.00509207 2hr 
1110005A03RIK RIKEN cDNA 1110005A03 gene (1110005A03Rik); mRNA 1.49491 0.0432868 2hr 
ABCC5 ATP-binding cassette; sub-family C (CFTR/MRP); member 5 1.22803 0.0441121 2hr 
FADS1 fatty acid desaturase 1 1.26151 0.0331181 2hr 
SEMA4B 
sema domain; immunoglobulin domain (Ig); transmembrane domain (TM) 
and short cytoplasmic domain; (semaphorin) 4B 1.23599 0.00276344 2hr 
ALPK2 alpha-kinase 2 1.22457 0.0279591 2hr 
SEC62 SEC62 homolog (S. cerevisiae) 1.23065 0.0314432 2hr 
IQCH IQ motif containing H 1.23077 0.0132759 2hr 
OTOP3 otopetrin 3 1.21251 0.0232051 2hr 
FAM70A family with sequence similarity 70; member A 1.33633 0.02221 2hr 
SKIV2L2 superkiller viralicidic activity 2-like 2 (S. cerevisiae) 1.27755 0.0150405 2hr 
MS4A2 membrane-spanning 4-domains; subfamily A; member 2 1.38084 0.0413534 2hr 
SBF2 SET binding factor 2 1.25571 0.022509 2hr 
PRL7B1 prolactin family 7; subfamily b; member 1 1.22265 
0.00021647
3 2hr 
DNAHC12 /// 
DNAHC7L dynein; axonemal; heavy chain 12 /// dynein; axonemal; heavy chain 7-like 1.22255 
0.00013574
1 2hr 
E230016M11RI
K RIKEN cDNA E230016M11 gene 1.28062 0.0362002 2hr 
TRIM24 tripartite motif-containing 24 1.21951 0.0182595 2hr 
DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1.2474 0.0315811 2hr 
NARF nuclear prelamin A recognition factor 1.21254 0.0340665 2hr 
1110020G09RIK RIKEN cDNA 1110020G09 gene 1.20117 0.0189711 2hr 
CLASP1 CLIP associating protein 1 1.205 0.0255391 2hr 
TSPYL5 testis-specific protein; Y-encoded-like 5 1.27133 0.0447402 2hr 
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RBMX RNA binding motif protein; X chromosome 1.24899 0.0341292 2hr 
RIF1 
Rap1 interacting factor 1 homolog (yeast); mRNA (cDNA clone 
IMAGE:4503215) 1.40755 0.0348304 2hr 
PTX3 pentraxin related gene 1.3553 0.0403225 2hr 
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Table VI-5.  List of 3’UTRs amplified from mouse genomic DNA used for 3’UTR luciferase analysis.  
Table shows gene abbreviation, length of 3’UTR (base pairs) and sequences of forward and reverse 
primers. 
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Table VI-5 
Gene Abbreviation 3'UTR Length Forward Primer Sequence Reverse Primer Sequence 
Apobec3 1060 (BP) TATACTCGAGCGATGTCTTGAGAGGC TATAGCGGCCGCGAGACAGACACCC 
CASR 771 (BP) TATACTCGAGCTCCTAATGGAGGGAG TATAGCGGCCGCCTGCCTTATAGAAT 
CCNE1 531 (BP) TATACTCGAGGACCAAACCTGCCATT TATAGCGGCCGCGACAGAGTTAAGAA 
CD151 784 (BP) TATACTCGAGCCACGATGATGTCAG TATAGCGGCCGCTTCGAGTGCTTATA 
ISX 555 (BP) TATAGCGATCGCGCAACTCTCCTCTCTCAGTGATG TATAGCGGCCGGCAGCCCAACAAAATGACGACAC 
LGALS 487 (BP) TATACTCGAGACCACGCCATGATCTA TATAGCGGCCGCGGCGCCATTCAGC 
TIAM1 2011 (BP) TATACTCGAGCACGGAGATATGACTT TATAGCGGCCGCAGGCACAGGGAAG 
USP30 1136 (BP) TATAGCGATCGCGAGTATAGGTCTGA TATAGCGGCCGCGACCAGAAGAGTC 
WDR5 1678 (BP) TATACTCGAGGTGACTGCTAAGTCCT TATAGCGGCCGCGGAACAAAATTACA 
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VII. Chapter 3: MicroRNA-21 (miR-21) Directly Targets Intestinal-Specific 
Homeobox in Granulosa Cells 
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1.  Abstract 
MicroRNA-21 (miR-21) has critical physiological functions in the ovary where it is important for 
maintaining optimal ovulation rates and in preventing cell death in granulosa cells.  The purpose of this 
project was to elucidate the molecular pathway of miR-21 action in granulosa through identification of 
functionally relevant miR-21 direct targets.  To identify these targets, cultured granulosa cells were 
treated with an oligonucleotide specific for miR-21 (LNA-21) and a non-specific LNA (LNA-NS) used as 
a control.  Eight hours after treatment, RNA was isolated and array analyses were performed (n=3).  
Array analysis revealed that loss of miR-21 caused overexpression of 372 and inhibition of 240 genes 
(612 total) when compared to cells treated with the control oligonucleotide.  There were 102 
overexpressed genes that contained potential miR-21 binding sites in their 3’UTR per bioinformatics 
analysis, implicating them as potential miR-21 direct targets.   Three genes, including calcium sensing 
receptor (CASR), cyclin E 1 (CCNE1) and intestinal-specific homeobox (ISX), were chosen for further 
analysis due to the previously identified functions in carcinogenesis and apoptosis.    3’ Untranslated 
Region (3’UTR) luciferase analysis in granulosa cells showed that miR-21 can bind to the 3’UTR of ISX, 
while no such binding was observed with the CASR and CCNE1 3’UTRs  Overexpression of miR-21 in 
granulosa cells caused ablation or near ablation of ISX protein.  Together these findings confirm that 
miR-21 is directly targeting and inhibiting ISX in granulosa cells.  ISX is a transcription factor that is 
known to negatively regulate scavenger receptor class B type 1 (SRB1), β,β-carotene 15,15′-
monooxygenase 1 (BCMO1) and retinoic acid receptor (RAR) expression in the intestine.  Knockdown of 
ISX with a siRNA specific for ISX in granulosa cells caused increased mRNA levels of each of these 
genes when compared to cells treated with a non-specific siRNA.  Additionally this treatment scheme 
caused induction of SRB1 protein levels.  This study has identified both direct (ISX) and indirect (SRB1, 
BCMO1 and RAR) targets of miR-21 in granulosa cells.  Each of these genes is known to function in a 
regulatory loop that impacts lipid and vitamin A uptake in the intestine.  Also BCMO1 SRB1 and retinoic 
acid signaling, is known to be important in ovarian development and/or function.  Direct and indirect 
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regulation by miR-21 of these genes suggests the potential of miR-21 regulating these functions in 
granulosa cells.   Identification of these genes is a critical first step towards elucidating miR-21’s 
mechanism of action in granulosa cells.      
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2.  Introduction 
MicroRNA are ~22 nucleotide length regulatory RNA that post-transcriptionally regulate gene expression 
through directly targeting 3’UTRs of mRNA that have complementary binding sites to its sequence [47-
50].  MicroRNA have been linked to many functional processes including cell proliferation, cell death, 
neuronal patterning and modulation of hematopoietic lineage differentiation [36].  In addition to 
regulating these processes, recent studies from our lab and others have implicated microRNA as critical 
for optimal female reproductive function.  Studies in which Dicer, a critical microRNA biogenic enzyme 
[31, 32], is knocked down in the female reproductive tract have led to distinct pathologies including 
morphological changes in the oviduct and uterus, compromised oocyte and embryo quality, impaired 
embryo transport and implantation rates, decreased ovulation rates and infertility [93-96].  Further studies 
from our lab have implicated a specific microRNA, microRNA-21 (miR-21) as having important 
functions in the ovary.  MiR-21 is induced by the LH surge and inhibition of miR-21 leads to impaired 
ovulation rates [98, 219].  Our lab has also shown that viability of mice murine cultured granulosa cells is 
significantly reduced when miR-21 is knocked down [219].   
These findings, which implicate miR-21 in critical physiological functions, parallel a substantial amount 
of previous research that has implicated miR-21 in pathological processes, specifically in cancer.  
Profiling experiments have shown that miR-21 is overexpressed in most solid tumors including lung, 
breast, colon, ovarian and pancreatic cancer [220].  Studies have also revealed that miR-21 has increased 
expression in carcinogenesis in both mice and humans with causal links between its expression and 
functions such as hypertrophy, migration and metastasis [221].  These findings have prompted research, 
which have identified a number of miR-21 direct targets across a variety of cancer cell lines.  These, 
include phosphatase and tensin homologue (PTEN) [126, 127], reverse-inducing-cysteine-rich protein 
with kazal motifs [128], tissue inhibitor of metalloproteinasis [128], leucine rich repeat interacting protein 
1 [129], bone morphogenetic protein receptor I [130], ras homologue gene family member b (RHOB) 
[131], sprouty2 (SPRY2) [132], mapsin [133], tropomyosin 1 (TPM1) [133, 134] and programmed cell 
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death 4 (PDCD-4)  [127, 132, 134, 135].  Our laboratory examined a select number of these targets in 
granulosa cells; PDCD-4, PTEN, TPM1 and SPRY2, and failed to identify a difference in protein 
expression of any of the genes following inhibition of miR-21 [99].  These findings suggests the 
possibility that miR-21 is directly targeting novel genes in granulosa cells.   
Due to its critical role in ovarian/granulosa cell physiology, the purpose of this study was to identify 
functionally relevant novel miR-21 direct targets in granulosa cells.  Since previous reports have shown 
that direct targets of microRNA have moderate changes in their mRNA levels [41, 42, 222], array 
expression analysis was used to determine steady state mRNA changes caused by miR-21 inhibition in 
granulosa cells.  Loss of miR-21 caused widespread changes in mRNA levels and bioinformatics analysis 
implicated many of these genes as potential miR-21 direct targets.  This study confirmed that intestinal-
specific homeobox (ISX) is a miR-21 direct target in granulosa cells.  Further studies showed that ISX 
regulated the expression of scavenger receptor class B type 1 (SRB1), β,β-carotene 15,15′-
monooxygenase 1 (BCMO1) and retinoic acid receptor (RAR).  These genes have been identified to be 
under the regulatory control of ISX and important in lipid uptake and vitamin A metabolism in the small 
intestine[215].  Also, both RAR and SRB1 have been implicated in critical roles in the ovary including 
meiotic initiation and steroidogenesis, respectively [223-225].  Through direct and indirect regulation of 
ISX, SRB1, BCMO1 and RAR, miR-21 may be regulating these functions in granulosa cells.         
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3.  Experimental Procedures     
Granulosa cell isolation and cell culture 
25 day old CF-1 female mice were sacrificed using cervical dislocation in accordance with the protocol 
for animal sacrifice approved by the Internal Care and Use Committee at the University of Kansas 
Medical Center.   Ovaries were removed and placed in M199 collection media (Sigma-Aldrich, St. Louis, 
MO.) supplemented with 10mM HEPES and 0.2% BSA.  Media was removed and replaced with M199 
media supplemented with 0 .5M sucrose and 1.8mM EGTA.  Ovaries were incubated in media in a 37
o
C 
water bath for 15 minutes.  After incubation ovaries were washed with M199 media (Sigma-Aldrich, St. 
Louis, MO.) 3X.  Antral follicles were poked with 28 gauge insulin needles (Becton Dickinson, Franklin 
Lakes, NJ.) to release granulosa cells.  Cells were transferred to a 15ml conical tube and spun for 15 
minutes at 0.8rcf.  Cells were plated in 6 well plates that had been previously coated with fibronectin at a 
density of 250,000 per well in DMEM F-12 HAM (Sigma-Aldrich, St. Louis, MO.) supplemented with 
10% FBS and 1% gentamicin.  Cells were incubated at 37
o
C, 5% CO2 for 48 hours prior to transfection.   
Array analysis 
After 48 hours in culture, granulosa cells were transfected with a locked nucleic acid specific for miR-21 
(LNA-21) (5’-+T+C+A GTCTGATAA+G+C+T A-3’)(Integrated DNA technologies, Coralville, IA.) or 
with a non-specific locked nucleic acid (LNA-NS) (5’+C+G+TCAGTATGCG+A+A+TC-3’) at a 
concentration of 5uM per well of a 6-well plate.  At 8 hours post transfection, cells were harvested and 
quality of RNA was assessed using Agilent Bioanalyzer 2001 (Agilent Incorp. Palo Alto, CA.).  RNA 
was biotin labeled and fragmented according to Affymetrix protocols.   Fragmented RNA from each 
sample was hybridized to the Affymetrix 430E 2.0 arrays (n=3, for each time point) and scanned using 
the gene array scanner (Affymetrix, Santa Clara, CA.).  For each chip analyzed the mean fluorescence 
was averaged to baseline fluorescence. 
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Cloning of ISX into siCHECK-2 (Promega) plasmid 
The 3’UTR of ISX, CASR and CCNE1 was amplified from wild type mouse genomic DNA.  Forward 
and reverse sequences  for ISX 5’- TATAGCTAGCGCGCAACTCTCCTCTCTCAGTGATG-3’ /5’-
TATAGCGGCCGG CAGCCCAACAAAATGACGACAC-3’ , CASR 5’-
TATACTCGAGCTCCTAATGGAGGGAG-3’/5’-TATAGCGGCCGCCTGCCTTATAGAAT and 
CCNE1 5’-TATACTCGAGGACCAAACCTGCCATT-3’/5’-
TATAGCGGCCGCGACAGAGTTAAGAA-3’.  Thirty-five cycles of amplification were performed 
using denaturing, annealing and extension conditions at 94
o
C, 55
o
C and 68
o
C degrees, respectively.  After 
amplification, ISX, CCNE1 and CASR was cut with XHO1 and Not1 (restriction sites located on the 5’ 
and 3’ end, respectively, of each amplified gene) restriction enzymes (New England Biolabs, Ipswich, 
MA.) at 37
o
C overnight using appropriate buffer.  After cutting, 3’UTRs were cloned into siCHECK-2 
(Promega, Madison, WI.) 3’ to the renilla translational stop codon using T4 DNA ligase enzyme and 
appropriate buffer (New England Biolabs, Ipswich, MA.) at 4 degrees overnight.   Plasmid with inserted 
construct was subsequently transformed into DH5α cells (Life Technologies, Carlsbad, CA.) using a 
standard transformation protocol and grown on LB ampicillin plates.   After overnight growth at 37
o
C, 
colonies were lifted and grown overnight at 37
o
C in LB ampicillin media.  DNA was isolated and clones 
were confirmed through sequencing.  
Site Directed Mutagenesis of ISX/siCHECK-2 plasmid 
Mutagenesis of the miR-21 site in the ISX 3’utr was performed using the GeneArt Site-Directed 
Mutagenesis PLUS Kit (Life Technologies, Carlsbad, CA.) per the manufacturers protocol.  Primer 
designed to perform the mutagenesis contained the following sequences;  5’-
GGATGAAGTCCAGAGTCATAGGCTCCT-3’ and 5’-GGTAAAAGAAGAGCCTATGACTCTGG-3’.  
The mutagenesis reaction mutated 5 bases on the 3’ end of the miR-21 site in the ISX 3’utr as indicated in 
figure 2.  Successful mutagenesis was confirmed through sequence analysis. 
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Luciferase analysis 
After 48 hours in culture, granulosa cells were co-transfected with sicheck2 plasmid containing the 3’utr 
of one of the genes along with pre-microRNA-21 (pre-miR-21) (an immature form of miR-21 that gets 
processed into the mature form using the endogenous cellular miRNA biogenic machinery) or pre-miR-
NS ( non-specific pre-miR used as a control).  Co-transfections were done using lipofectamine 2000 
(Invitrogen, Carlsbad, CA.) per the manufacturers’ protocol.  The vectors were transfected at a 
concentration of 10ng and pre-miRs were transfected at 5uM, per well of a 6-well plate.  24 hours after 
transfection, cells were harvested and lysed using passive lysis buffer (Promega, Madison, WI.).  Lysates 
were prepared for luciferase assay using the dual luciferase reporter assay system (Promega, Madison, 
WI.) per the manufacturers’ protocol.  Luciferase assays were performed on the Berthold Lumat LB 9501 
Luminometer  (Wallac, Gaithersburg, MD.).    
Immunoblotting 
After 48 hours in culture, granulosa cells were transfected under two different treatment schemes 
followed by probing with different antibodies per each treatment scheme (described below).  24 hours 
after transfection cells were harvested and lysed in hypotonic buffer containing 20mM NaCL, 20mM 
Tris-HCl and 0.1% Triton X-100.  After centrifugation at 10,000 X G for 10 minutes to remove cellular 
debris, protein concentration of the supernatant was quantified using the Bio-Rad protein assay (Bio-Rad 
Laboratories, Berkeley, CA.).  Fifteen micrograms of each sample was added to appropriate volume of 
4X sample buffer (4 mL of glycerol, 0.8g of sodium dodecyl sulfate [SDS], 2.5 mL of 1 M Tris-HCl, 
8mL of H2O, 0.05% w/v bromophenol blue).  After heating at 95
o
C for 5 minutes, proteins were resolved 
on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis in 1X running buffer (4.5 g Tris-
base, 21.6 glycine, 2 g SDS, 2 L dH2O).  The proteins were subsequently transferred to a polyvinylidene 
fluoride membrane using 1X transfer buffer (6.06 g ofTris-Base, 28 g glycine, 0.2 g SDS, 1,600 mL 
dH2O, 400 mL MeOH).  Membranes were blocked in 5% milk in 1X Tris-buffered saline 0.1% Tween 
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(TBS-T) for 2 hours.  Before and after secondary antibody incubations membranes were washed 3X with 
TBS-T.  West Pico Chemiluminescent (ThermoScientific, Rockford, Il.)substrate was used to visualize 
the protein antibody complexes.   
 
The first treatment was with pre-miR-21 and pre-miR-NS (control)(Life Technologies, Carlsbad, CA.) at 
the concentration of 5uM per well of a 6-well plate using lipofectamine 2000, per the manufacturer’s 
protocol.   Primary antibody used was anti-ISX (Santa Cruz Biotech., Santa Cruz, CA.)(SC-86151) at a 
concentration of 1:250 in TBS-T.  Secondary antibody used was anti-rabbit IgG at a concentration of 
1:1000 in TBS-T.  The second treatment was siRNA-ISX and siRNA-NS (control)(Life Technologies, 
Carlsbad, CA.) at a concentration of 5uM per well of a 6-well plate using lipofectamine 2000, per the 
manufacturer’s protocol.  The primary rabbit polyclonal antibody used was anti-SRB1 (Novus 
Biologicals, Littleton, CO.)(NB400-104) at a concentration of 1:1,000 in 5% milk in TBS-T.  Secondary 
antibody used was anti-rabbit IgG at a concentration of 1:5,000 in TBS-T.  After completing the ISX and 
SRB1 western each blot was stripped in stripping buffer (10 ml of Sodium Dodecyl Sulfate, 390ul of 2-
mercaptoethanol, 3.125ml of 1M Tris-HCl (pH 6.8) and 36.485ml of H2O) for 25 minutes at 50
o
C.  After 
stripping, blots were blocked and western was completed as described above with anti-Actin (Santa Cruz 
Biotech., Santa Cruz, CA.) used as the primary antibody and anti-goat IgG was as the secondary.   
Antibody conditions were 1:1,000 in 5% milk in TBS-T and 1:5,000 in 5% milk in TBS-T, for the 
primary and secondary antibodies, respectively.   
 
Quantitative RT-PCR 
After 48 hours in culture, granulosa cells were treated with siRNA-ISX and siRNA-NS (Life 
Technologies, Carlsbad, CA.) at a concentration of 5uM per well of a 6 well plate using lipofectamine 
2000 per the manufacturer’s protocol.  24 hours after treatment, RNA was isolated using TriZol per the 
manufacturer’s protocol.  250ng of RNA was used in reverse transcription reactions.  cDNA was made 
using the miScript II RT Kit (Qiagen, Hilden, Germany) per the manufacturers protocol.  QRT-PCR 
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analysis was performed to test for amplification levels of RAR, BCMO1, SRB1, CDX2 and ISX between 
the siRNA-ISX and siRNA-NS treatment groups.  Primers used for each were (RAR) 5’-
AGTACTGCCGGCTGCAGAA-3’/ 5’-TCGCACCGACTCCTTGGA-3’, (BCMO1)5’-
TTTCCAAAGCTTTCTCCTACTTGTCT-3’/5’-CCACATTTCATCATCTTGATCAGA-3’, (CDX2)5’-
GAGCTGGCTGCCACACTTG-3’/5’-GCTCTGCGGTTCTGAAACCA-3’, (ISX)5’-
GTGTCTGGTCCTGTGCTGACA-3’/5’-CTGAGAGAGTAGGCAGCATTCTGT-3’ and (u6)5-
’CTCGCTTCGGCAGCACA-3’/5’-AACGCTTCACGAATTTGCGT-3’ (used as a control) .  Each 
reaction was performed on the ABI Prism 7900HT Sequence Detection system (Life Technologies, 
Carslbad, CA.) under the conditions of stage 1-50.0
o
/2:00, stage 2- 95.0
o
/10:00, stage 3-95.0
o
/:15 and 
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o
/1:00, stage 3-95.0
o
/:15, 60.0
o
/:15 and 95.0
o
/:15.  Each sample was performed in triplicates and the 
average was used to determine the relative expression levels between it and U6.  To calculate relative fold 
change, the delta-delta CT method [226] was used. 
 
Statistical analysis 
For each of the quantitative assays performed in this study (3’utr luciferase assays, western blotting, and 
qRT-PCR) students t-tests were formed to determine if there was a statistical difference between control 
and experimental treatment groups.  Each assay used an N=3 and N=4, as indicated in the results.  
Statistical significance was set at P<0.05 for each assay analyzed.  Statistical analysis was not performed 
in the ISX blot shown in the results (figure 3) as the ISX signal was ablated or nearly ablated after pre-
miR-21 treatment.   Instead, all 4 experiments performed are shown in results. 
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4.  Results and Tables/Figures 
Steady-state mRNA changes in granulosa cells after loss of miR-21 
MiR-21’s effect on steady state mRNA levels in granulosa cells was assessed to identify miR-21 direct 
targets.  At 8 hours after miR-21 knockdown in granulosa cells arrays were performed.  There were a total 
of 611 genes that were dysregulated with 372 being overexpressed and 240 being inhibited.  Of the 372 
overexpressed genes following loss of miR-21, 102 had potential miR-21 sites in their 3’UTR according 
to bioinformatics algorithms (Table VII-2) (microT, miRanda, PicTar, PITA, TargetScan).  Three genes, 
CASR (increased 1.2 fold), CCNE1 (increased 1.3 fold) and ISX (increased 1.3 fold), were chosen for 
further analysis due to their previously identified role in carcinogenesis and apoptosis (Table 1.).    
3’UTR luciferase analysis of CASR, CCNE1 and ISX 
To determine if miR-21 binds to the 3’UTRs of CASR, CCEN1 and/or ISX, the 3’UTR of each was 
separately cloned into the siCHECK-2 (Promega, Madison, WI.) vector.  Granulosa cells were co-
transfected with siCHECK-2 construct and pre-miR-21.  Control cells were treated with a non-specific 
pre-miR (pre-miR-NS).    The renilla/firefly ratio of siCHECK-2 containing CASR and CCNE1 3’UTRs 
did not change when miR-21 was overexpressed (Figure VII-1).  However, overexpression of miR-21 did 
cause the renilla/firefly ratio of siCHECK-2 containing the ISX 3’UTR to decrease 30.1% when 
compared to the pre-miR-NS treated cells (n=3, p<.05) (Figure VII-1).  To determine if renilla/firefly 
ratio change was due to specific binding, 5 bases of the 3’UTR of ISX were mutated at the 3’ end of its 
miR-21 putative binding site (TargetScan) (Figure VII-2).  An independent experiment in which 
granulosa cells were treated with siCHECK-2 containing the mutated ISX 3’UTR resulted in 
renilla/firefly ratio remaining the same between the pre-miR-NS and pre-miR-21 treated cells (n=3), 
while there was a 34.0% decline in the renilla/firefly ratio when miR-21 was overexpressed in cells 
treated with the siCHECK-2 vector containing with wild type ISX 3’UTR (P<0.05, n=3) (Figure VII-2).  
Together these results show that miR-21 binds directly to the ISX 3’UTR.  
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ISX protein expression levels after miR-21 overexpression     
To confirm that miR-21 is directly targeting ISX, cultured granulosa cells were treated with pre-miR-21 
to overexpress miR-21 and pre-miR-NS, which was used as a control.  Overexpression of miR-21 caused 
ablation or near ablation of ISX expression levels when compared to the pre-miR-NS treated cells 
(P<0.05, n=4) (Figure VII-3), suggesting that miR-21 is regulating ISX protein levels in granulosa cells.  
This western result along with the luciferase analysis, reveal that miR-21 is directly targeting ISX in 
granulosa cells. 
ISX regulation of RAR, BCMO1 and SRB1 
RAR, BCMO1, SRB1 and CDX2 have been previously identified to be under ISX regulation in the small 
intestine.   To determine if ISX regulates these genes in granulosa cells, cultured granulosa cells were 
treated with siRNA specific for ISX (siRNA-ISX) and a non-specific siRNA (siRNA-NS).  qRT-PCR 
analysis revealed that siRNA-ISX treatment caused an 81.7, 80.1 and 36.8 fold increase in RAR, BCMO1 
and SRB1 mRNA expression levels, respectively (Figure VII-4).  ISX inhibition had no effect on CDX2 
expression levels (Figure VII-6).  Treatment of cells with siRNA-ISX was effective in reducing the 
expression of ISX mRNA 130.5-fold when compared to siRNA-NS treated cells (Figure VII-6).  Western 
blotting revealed that inhibition of ISX in granulosa cells using siRNA-ISX caused a 3-fold increase in 
SRB1 protein expression levels when compared to control treated cells (p<0.05, n=4) (Figure VII-5). 
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Table VII-1.  List of 3 select genes, cyclin E1 (CCNE1), calcium sensing receptor (CASR) and intestinal-
specific homeobox (ISX), upregulated in granulosa cells due to LNA-21 treatment whose 3’UTRs were 
analyzed using the luciferase assay system.  Genes were chosen due to their tumorigenic/apoptotic 
functions identified in other tissues. 
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Table VII-1 
Gene Name 
Gene 
Symbol 
Fold 
Increase 
Function 
cyclin E1 CCNE1 
1.26 fold 
increase 
important for cell cycle progression 
calcium sensing 
receptor 
CASR 
1.24 fold 
increase 
GPCR important in calcium homeostasis 
intestinal-specific 
homeobox 
ISX 
1.26 fold 
increase 
transcription factor involved in inflammatory 
responses and cellular differentiation 
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Figure VII-1.  Identification of ISX as a direct target of miR-21 in granulosa cells.  Each 3’UTR was 
separately cloned into siCHECK-2 (Promega, Madison, WI.) and transfected into cultured granulosa cells.  
Pre-miR-21 treatment caused a 30.1% percent reduction in the renilla/firefly ratio of cells transfected with 
siCHECK-2 containing the ISX 3’UTR when compared to pre-miR-NS treatment (n=3, p<.05).  There 
was no statistical change in the renilla/firefly ratio between the pre-miR-NS and pre-miR-21 treatments in 
granulosa cells transfected with the siCHECK-2 vector containing the 3’UTRs of CCNE1 or CASR 
(n=3).  *Means +/- SEM are statistically different (p<0.05). 
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Figure VII-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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Figure VII-2.  Independent analysis of the ISX 3’UTR miR-21 wild-type and the ISX 3’UTR miR-21 
mutant.  Pre-miR-21 treatment cased a 34.0% decline in the renilla/firefly ratio in the wild-type ISX 3’utr 
transfected cells when compared to the pre-miR-NS treatment (n=3, p<.05).  Conversely there was no 
statistically significant difference in the renilla/firefly ratio observed between the pre-miR-NS and pre-
miR-21 treatments in the ISX 3’UTR mutant (n=3).  The boxes show putative miR-21 binding site within 
the ISX 3’UTR and the disrupted bases (shown in red) in the ISX 3’UTR after mutagenesis reaction.  
*Means +/- SEM are statistically different (p<0.05). 
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Figure VII-2 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
  3' aguuguagUCA-GAC-UAUUCGAu 5' –miR-21 
                                  ||| |  |   | 
 5' ggggaugaAGUCCAGAGUCATAGg 3' –ISX 3’utr      
   3' aguuguagUCA-GAC-UAUUCGAu 5'- miR-21 
                                  |||  | | |||||||  
 5' ggggaugaAGUCCAGAAUAAGCUg 3‘-ISX 3’utr 
 
* 
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Figure VII-3.  Western analysis of ISX after miR-21 overexpression in granulosa cells.  4 separate 
experiments are represented in which granulosa cells were treated with a non-specific pre-miR (pre-NS) 
used as a control or a pre-miR specific for miR-21 (pre-21).  Overexpression of miR-21 caused complete 
or near complete ablation of ISX signal in each of the 4 experiments.  
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Figure VII-3 
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Figure VII-4.  QRT-PCR analysis of retinoic acid receptor (RAR), β,β-carotene 15,15′-monooxygenase 1 
(BCMO1), and scavenger receptor class B type 1 (SRB1) after ISX inhibition in granulosa cells.  RAR, 
BCMO1 and SRB1 were upregulated 81.7 fold, 80.1 fold and 36.8, respectively (n=3, p<.05, for each 
gene tested) after treatment with siRNA-ISX when compared to the siRNA-NS control treatment.  
*Means +/- SEM are statistically different (p<0.05).    
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Figure VII-4 
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Figure VII-5.  SRB1 protein expression levels after inhibition of ISX.  Treatment of cultured granulosa 
cells with siRNA-ISX caused a 3-fold increase in SRB1 protein levels when compared to cells treated 
with si-RNA-NS (n=3, p<.05).   *Means +/- SEM are statistically different (p<0.05).      
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Figure VII-5 
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5.  Discussion 
Loss of miR-21 in ovarian granulosa cells can elicit profound effects both in vivo through blockade of 
ovulation and in vitro through induction of apoptosis [99].  However, analysis of numerous mir-21 targets 
identified previously in cancer cell lines has failed to identify a single positive target in ovarian granulosa 
cells [99].  The current study set out to identify direct miR-21 target genes in granulosa cells, as a 
mechanism to better understand how this post-transcriptional modulator could affect ovarian function.   
Intestinal-specific homeobox (ISX) mRNA expression was found to be moderately yet statistically 
induced 1.3-fold 8 hours after blockade of miR-21 activity in granulosa cells.  Bioinformatic analysis 
showed that the 3’UTR of ISX contains a nucleotide sequence that has perfect homology with the seed 
sequence or the first seven bases of the 5’ end of the mature form of miR-21.  Luciferase expression 
analysis of granulosa cells treated with a luciferase vector containing the ISX 3’UTR and a miR-21 
overexpression oligonucleotide, revealed that miR-21 does regulate gene expression and that loss of the 
miR-21 recognition site prevented miR-21 action.  Lastly, ISX expression was ablated after miR-21 
overexpression in granulosa cells confirming that ISX is a direct target of miR-21 in granulosa cells. 
Originally identified in the intestine [227], ISX was shown to be highly expressed in the epithelium from 
the duodenum to the proximal colon, where it acts as a repressor of multiple genes within the intestine 
[228].   A recent study by Hsu et al., however, suggests that ISX can also act as a proimmflammatory 
homeobox gene, as they identified its ectopic expression in hepatocellular carcinoma (HCC) cells [229].  
Even more interesting, in the HCC cells, ISX was shown to be a transcriptional activator of the cyclin D1 
gene [229].  Thus, it is possible that this transcription factor could be both a positive and negative 
regulator of gene transcription dependent upon cellular context.   The ectopic expression in the HCC is 
the first to describe ISX in a cell other than intestine, and ours is the first to show expression in a non-
transformed ovarian tissue, specifically granulosa cells.  As a homeobox gene, ISX, might be expected to 
play essential roles in cell survival, cell proliferation and inhibition of cell differention, a feature common 
to other HOX genes [230].   Prior to ovulation the granulosa cells are highly proliferative and require a 
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constant series of hormonal signals to remain viable and block atresia [89].  Following the ovulatory 
surge of LH, the granulosa cells terminally differentiate and undergo radical changes in cell morphology 
associated with the conversion to a highly steroidogenic cell [231].   Consistent with these cellular 
changes, ISX protein was present in granulosa cells before the LH surge and was reduced by 
overexpression miR-21, which in vivo is upregulated by the LH-surge [232].    
 Dietary carotene is typically converted to vitamin A (all-trans-retinol) in the intestine by β,β carotene-
15,15’monooxygenase (BCMO1) and vitamin A in turn serves well known roles in vision, reproduction, 
immune function as well as cell differentiation [233].   Recent studies have implicated scavenger receptor 
class B type 1 (SCARB1) in the uptake of carotenoids and other lipid soluble vitamins [234], in addition 
to its well established roles in transfer of cholesterol from high density lipoproteins [223].   Knockout of 
ISX caused significant changes in intestinal gene expression including a significant increase in the 
expression of SRB1 and BCMO1, indicating that the ISX transcription factor might be acting as a 
repressor and in the presence of high vitamin A and downregulate these genes while the absence of the 
vitamin A derived retinoic acid stimulates ISX expression to limit both metabolism and uptake [228].   
Based on these observations and the known expression of these key players in ovarian granulosa cells 
[216, 217, 235, 236], we examined whether loss of ISX was able to influence downstream target genes.   
Knockdown of ISX by siRNA treatment in cultured granulosa cells increased SRB1, BCMO1 and RAR 
mRNA expression, all three of which have been previously shown to be under negative influence of ISX 
in the intestine [215, 228].   These findings suggest that ISX may regulate these genes in granulosa cells 
and that vitamin A uptake/metabolism may be under ISX control in granulosa cells.  This hypothesis 
carries significance because vitamin A has previously been shown to be important for female 
reproduction and development of the female germ line [237].  Bovine and rodent studies have shown that 
vitamin A is critical for oocyte meiosis and oocyte maturation and that, under the appropriate conditions, 
vitamin A supplementation increases fertility rates [238-240].  Indeed, meiotic resumption has been 
shown to be mediated throughout retinoic acid, an active vitamin A metabolite and that germ cells 
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deficient in all-trans retinoic acid remained in their undifferentiated state and failed to enter meiosis [239].  
Since paracrine signaling between the oocyte and granulosa cells is a known mechanism of oocyte 
development and function [241], ISX regulation of RAR in granulosa cells may be a control mechanism 
of meiotic resumption in female germ cells.  Retinoic acid signaling, in addition to functioning in meiosis 
and maintaining viable germ cells during oogenesis, is also essential for cellular growth regulation, 
differentiation and cell death in a variety of tissues during fetal development [235].  Each of these 
functions may also be under ISX control through the regulation of RAR in granulosa cells.  
ISX regulation of SCARB1 may also function to regulate steroidogenesis in the granulosa cells.  Previous 
studies have shown that SCARB1 is highly expressed in rodent steroidogenic cells where it plays a 
critical role in cholesterol uptake and steroidogenesis [223].  Studies have also shown that SRB1 
expression is hormonally regulated by both FSH and LH [216, 217].  Significantly, previous research has 
revealed that the luteinizing surge of LH leads to increased signal intensity of SCARB1 in granulosa cells 
and in luteinized granulosa cells, thereby causing increased cholesterol uptake and steriodogenesis [216].  
Studies from our lab have shown that miR-21 is induced by the LH surge [98].  If miR-21 is directly 
targeting and knocking down ISX after the LH surge, this could be a control mechanism whereby ISX no 
longer represses SRB1, leading to increased steroidogenesis and luteinization in granulosa cells.    
Due to ISX’s regulation of BCMO1, SRB1 and RAR, any and, potentially, all of these functions may be 
under ISX control in granulosa cells/the ovary.  And since this study has confirmed that ISX is under 
miR-21 direct control in granulosa cells, miR-21 may be the master regulator of these functions through 
direct regulation of ISX and indirect regulation of BCMO1, SRB1 and RAR.   Functional studies will 
need to be performed to determine if miR-21/ISX regulates any/all of the above described functions.   
In addition to identifying a novel miR-21 direct target that may have functional relevance in granulosa 
cells, results from this study are consistent with previous studies that have investigated the role of 
microRNA on steady-state mRNA levels.  Previous investigations have reported that microRNA modestly 
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regulate large number of target mRNA [14, 40, 41] and that mRNA regulated by microRNA tend to be 
overrepresented with seed sequences that match the mRNA [42]; a finding which strongly suggests that, 
at least some, microRNA direct targets show mRNA destabilization.  This study identified 612 genes that 
were moderately, yet, statistically differentially regulated 8 hours after loss of miR-21 when compared to 
control treated cells.  Bioinformatic analysis identified 102 of these genes as being potential miR-21 
direct targets based solely on the presence of a recognition site.  However, until each of these individual 
genes are subsequently investigated through use of 3’UTR reporter assays/western blot analyses, we 
cannot conclude of their relevance to granulosa cell function.    
Previous reports from our lab have already shown the physiological importance of miR-21 in the ovarian 
function and in granulosa cells.  Functional studies will need to be performed to determine if miR-21 
which is induced by the LH surge is able to then repress the translation or induce degradation of ISX 
mRNA.  In turn, through direct control of ISX levels, genes downstream of this transcriptional repressor 
are able to increase and many of these have established roles in steroidogenesis.   Along with elucidating 
key molecular events under miR-21 control in granulosa cells, this study has also confirmed previous 
reports that microRNA affect steady-state mRNA levels and even cause destabilization of the message 
levels of the genes that microRNA directly target.  Further biochemical and molecular assays will be 
needed to determine if any of the remaining putative miR-21 direct targets identified through 
bioinformatics are under miR-21 direct control and, if so, whether or not they have functional relevance in 
granulosa cells/the ovary.  
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6.   Supplementary Data 
Figure VII-6.  QRT-PCR analysis of intestinal-specific homeobox (ISX) and caudal-related homeobox 
(CDX2) after ISX knockdown.  There was a 130.5 decrease in ISX mRNA expression 24 hours after 
treatment with a siRNA-ISX when compared to cells treated with siRNA-NS.  There was no statistical 
difference in CDX2 mRNA expression levels between the cells treated with siRNA-NS and siRNA-ISX.   
*Means +/- SEM are statistically different (p<0.05).   
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Figure VII-6 
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Table VII-2.  List of 102 genes that were upregulated 8 hours after loss of miR-21 and that contained 
potential miR-21 binding sites.  Table lists gene symbol, gene name, fold change and p-value for each 
gene.  Algorithms used were microT, miRanda, TargetScan, PicTar and PITA.   
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Table VII-2 
Gene Symbol Gene Name Fold Change P-value 
KCNA1 potassium voltage-gated channel; shaker-related subfamily; member 1 1.24066 0.0381492 
MAP2K3 mitogen-activated protein kinase kinase 3 1.22371 0.0308353 
2310035C23RIK RIKEN cDNA 2310035C23 gene 1.2748 0.0382897 
RALGPS1 Ral GEF with PH domain and SH3 binding motif 1 1.25791 0.0467209 
STX2 syntaxin 2 1.23431 0.034218 
CASR calcium-sensing receptor 1.23596 0.0237921 
CNNM4 cyclin M4 1.2244 0.0234587 
ISX intestine specific homeobox 1.26309 0.0284002 
ATP8A1 ATPase; aminophospholipid transporter (APLT); class I; type 8A; member 1 1.24654 0.0369261 
PSD2 pleckstrin and Sec7 domain containing 2 1.2342 0.0287654 
CD244 CD244 natural killer cell receptor 2B4 1.2094 0.0378144 
NEK6 NIMA (never in mitosis gene a)-related expressed kinase 6 1.24016 0.0386376 
RNF144A ring finger protein 144A 1.33035 0.0071275 
DMRTC1A DMRT-like family C1a 1.22113 0.0330858 
SEL1L deoxyribonuclease 1-like 2 /// similar to Dnase1l2 protein 1.45314 0.0470193 
TPCN1 two pore channel 1 1.38189 0.0046422 
KCND3 potassium voltage-gated channel; Shal-related family; member 3 1.24132 0.0364306 
EPHB2 Eph receptor B2 1.20284 0.0442559 
LOC100044065 /// 
ODZ1 
similar to odd Oz/ten-m homolog 1 (Drosophila) /// odd Oz/ten-m homolog 1 
(Drosophila) 1.44758 0.0263521 
GALNT13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 
13 1.32545 0.0283911 
MSMB beta-microseminoprotein 1.36798 0.0351251 
BCL7A B-cell CLL/lymphoma 7A 1.22852 0.0094923 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.24707 0.011334 
DUSP8 dual specificity phosphatase 8 1.41019 0.0081411 
PPP1R10 
predicted gene; 100039405 /// similar to protein phosphatase 1; regulatory subunit 10 
/// protein phosphatase 1; regulatory subunit 10 1.33757 0.0459527 
MC1R melanocortin 1 receptor 1.24041 0.0135792 
KLRB1C killer cell lectin-like receptor subfamily B member 1C 1.30395 0.0477138 
AK3L1 adenylate kinase 3-like 1 /// similar to adenylate kinase 4 1.31706 0.0401146 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 1.19567 0.0294399 
LOC100046704 /// 
NRAS similar to neuroblastoma ras oncogene /// neuroblastoma ras oncogene 1.22974 0.0428806 
FBLN1 fibulin 1 1.31901 0.0485345 
NUTF2 nuclear transport factor 2 1.29939 0.0176036 
COPG coatomer protein complex; subunit gamma 1.27054 0.0212557 
SYS1 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) 1.2427 0.0289906 
SETMAR SET domain and mariner transposase fusion gene 1.20264 0.0325313 
ANAPC11 
Anaphase promoting complex subunit 11; mRNA (cDNA clone MGC:35764 
IMAGE:5356010) 1.27847 0.0318457 
NRP neural regeneration protein 1.38904 0.0263308 
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SLC10A7 solute carrier family 10 (sodium/bile acid cotransporter family); member 7 1.33827 0.0411596 
NFIX heat shock transcription factor family member 5 1.29147 0.0230708 
2210020M01RIK RIKEN cDNA 2210020M01 gene 1.21661 0.0173907 
UCP2 
Uncoupling protein 2 (mitochondrial; proton carrier); mRNA (cDNA clone MGC:13955 
IMAGE:4205625) 1.3288 0.0010800 
CAP2 CAP; adenylate cyclase-associated protein; 2 (yeast) 1.31103 0.0448868 
4833439L19RIK RIKEN cDNA 4833439L19 gene 1.22641 0.0294885 
KCNIP3 Kv channel interacting protein 3; calsenilin 1.31158 0.0268974 
SH3GL3 SH3-domain GRB2-like 3 1.21961 0.0054183 
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1.25029 0.0014307 
SYS1 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) 1.2427 0.0289906 
NPCD /// NPTXR neuronal pentraxin with chromo domain /// neuronal pentraxin receptor 1.2506 0.0418691 
FOXS1 forkhead box S1 1.34367 0.0314605 
ETV1 ets variant gene 1 1.32093 0.0459477 
RAB36 RAB36; member RAS oncogene family 1.25816 0.0348 
MAPK12 mitogen-activated protein kinase 12 1.2472 0.0029408 
2810046L04RIK RIKEN cDNA 2810046L04 gene 1.23751 0.0022706 
NEUROG1 neurogenin 1 1.20242 0.0116106 
HSF5 heat shock transcription factor family member 5 1.29147 0.0230708 
RECQL RecQ protein-like 1.19606 0.0401784 
GNAS GNAS (guanine nucleotide binding protein; alpha stimulating) complex locus 1.20489 0.0259956 
4930579E17RIK RIKEN cDNA 4930579E17 gene 1.19629 0.0332697 
SCN3B sodium channel; voltage-gated; type III; beta 1.20291 0.0124925 
1700065D16RIK RIKEN cDNA 1700065D16 gene 1.20812 0.0120007 
TMEM29 transmembrane protein 29 1.40516 0.0056755 
PHC2 polyhomeotic-like 2 (Drosophila) 1.27718 0.0446983 
GHR growth hormone receptor 1.22006 0.003078 
TTC28 tetratricopeptide repeat domain 28 1.23915 0.0218533 
CCNY /// 
LOC100044842 cyclin Y /// similar to cyclin fold protein 1 1.20531 0.0079419 
CCNE1 cyclin E1 1.25368 0.015062 
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 1.21405 0.0434991 
FBXO21 F-box protein 21 1.2031 0.0340304 
MYLPF myosin light chain; phosphorylatable; fast skeletal muscle 1.27022 0.0271005 
MCM5 minichromosome maintenance deficient 5; cell division cycle 46 (S. cerevisiae) 1.28009 0.0419356 
GRHL2 grainyhead-like 2 (Drosophila) 1.45489 0.04115 
LEPR leptin receptor 1.30297 0.0468672 
EG232599 Predicted gene; EG232599; mRNA (cDNA clone MGC:156005 IMAGE:40129691) 1.20106 0.0220952 
EDA ectodysplasin-A 1.23257 0.0104525 
LDLR low density lipoprotein receptor 1.41719 0.0391926 
ZFP651 zinc finger protein 651 1.20411 0.0289022 
CALR3 calreticulin 3 1.31668 0.0240547 
CENPA Centromere protein A; mRNA (cDNA clone MGC:13888 IMAGE:4018429) 1.3344 0.0445517 
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USP30 ubiquitin specific peptidase 30 1.19824 0.0359382 
FGFR1 fibroblast growth factor receptor 1 1.1935 0.0160073 
ZFP473 zinc finger protein 473 1.21327 0.0440109 
POU2F1 POU domain; class 2; transcription factor 1 1.21115 0.0119038 
ACOT12 acyl-CoA thioesterase 12 1.273 0.0254415 
COX4NB COX4 neighbor 1.21692 0.0360243 
GAS7 growth arrest specific 7 1.22461 0.049252 
NTSR1 neurotensin receptor 1 1.27018 0.020129 
SLC12A3 solute carrier family 12; member 3 1.32589 0.0447393 
C530008M17RIK RIKEN cDNA C530008M17 gene 1.2 0.0414148 
VPRBP Vpr (HIV-1) binding protein 1.24638 0.0180449 
PVT1 plasmacytoma variant translocation 1 1.22902 0.0187565 
SYT17 synaptotagmin XVII 1.20427 0.013803 
GABRB3 gamma-aminobutyric acid (GABA) A receptor; subunit beta 3 1.22451 0.0307998 
ASAH2 N-acylsphingosine amidohydrolase 2 1.21031 0.0122681 
5730469M10RIK RIKEN cDNA 5730469M10 gene 1.2101 0.0084849 
ELMO1 engulfment and cell motility 1; ced-12 homolog (C. elegans) 1.27493 0.0432414 
ENPEP glutamyl aminopeptidase 1.29743 0.0200332 
ACADL acyl-Coenzyme A dehydrogenase; long-chain 1.22746 0.0471311 
ZHX3 zinc fingers and homeoboxes 3 1.22889 0.0022496 
ROR1 receptor tyrosine kinase-like orphan receptor 1 1.20987 0.0119589 
DMC1 
DMC1 dosage suppressor of mck1 homolog; meiosis-specific homologous 
recombination (yeast) 1.2226 0.0038219 
SEC11A SEC11 homolog A (S. cerevisiae) 1.29546 0.0429056 
EOMES eomesodermin homolog (Xenopus laevis) 1.27725 0.0340839 
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VIII. Chapter 4: Roles of MicroRNA-21 (miR-21) and Programmed Cell 
Death 4 (PDCD-4) in Human Uterine Leiomyomas (ULMs) 
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1.  Abstract 
Uterine fibroids (ULM) express increased microRNA-21 (miR-21), yet this oncomir's role in ULM, the 
leading cause of hysterectomies, is unknown. This study sought to determine if  expression of 
programmed cell death 4 (PDCD-4), a well-known target of  miR-21, is altered in autologous leiomyoma 
and myometrial tissues and  whether miR-21 regulates PDCD-4 expression, apoptosis, and 
global  translation in immortalized myometrial (UtM) and leiomyoma (UtLM)  cell lines.  Leiomyoma 
tissues robustly expressed the full-length 51kDA isoform of PDCD-4, while normal myometrial tissue 
had negligible  expression, but instead expressed a 29kDA isoform not seen in  leiomyoma tissues. 
Similarly, UtLM cells expressed elevated miR-21 compared to UtM cells and a pattern of PDCD-4 
consistent with  autologous tissues.  Knockdown of miR-21 increased PDCD-4 levels in UtM cells and 
UtLM cells, indicating that it can regulate PDCD-4 expression, but this regulation was limited.  Loss of 
miR-21 also increased cleavage of caspase-3 (apoptosis marker) and increased phosphorylation of 
elongation factor -2 (marker of reduced  translation) in both cell lines.  Both the novel differential PDCD-
4  isoform expression seen in these autologous tissues and the increased  PDCD-4 in leiomyomas were 
unexpected.  Elevated leiomyoma miR-21 levels would be predicted to decrease PDCD-4 levels, thus 
leiomyomas  differ from other tumors where loss of PDCD-4 has been associated with  tumor 
progression.  Our studies indicate regulation of PDCD-4 expression is not a primary miR-21 function in 
leiomyomas, but instead  miR-21 is able to impact cellular apoptosis and translation, through  unknown 
targets, in a manner consistent with its involvement in the  pathophysiology of ULM. 
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2.  Introduction 
Human uterine leiomyomas (ULMs) are benign tumors located in the smooth muscle of the myometrium.   
They are clinically apparent in ~25% of reproductive-aged women but the overall incidence is between 70 
and 80% [156].  ULMs can cause abnormal uterine bleeding, pelvic pressure, pain, and reproductive 
dysfunction and they are the most common risk factor for hysterectomy resulting in 200,000 annually in 
the U.S. [160].   While the etiology that leads to the development of ULMs is unknown, the ovarian 
steroid hormones, estrogen and progesterone, as well as genetic abnormalities have both been implicated 
in the development of ULMs [172, 185, 242, 243].  Numerous studies have implicated microRNAs 
(miRNA) as critical regulators of many disease processes including cancer [220, 244].   A consistent 
finding observed across ULM miRNA expression studies comparing leiomyoma tissue to autologous 
myometrial tissue is the induction of miR-21 in ULM tissue [202-204].  Aberrant expression of miR-21 in 
a number of human cancers including breast, cervical, ovarian, hepatocellular, esophageal, prostate and 
lung B cell lymphoma has led to miR-21 being referred to as an oncomiR [220, 244].    While miR-21 has 
received a great deal of attention due to its role in other cancers, little is known regarding the role that 
miR-21 plays in ULM etiology.  
 Many functionally important direct targets of miR-21 that regulate apoptosis and/or 
tumorigenesis have been identified.  These include reversion-inducing-cysteine-rich protein with Kazal 
motifs (RECK), sprouty 2 (SPRY2), phosphatase and tensin homologue (PTEN), T lymphoma and 
metastasis gene 1 (TIAM1) and tropomyosin 1 amongst others (TPM1) [220].  Another well studied miR-
21 target transcript is programmed cell death-4 (PDCD-4) [135, 220].  PDCD-4 has many important 
functions including cell cycle regulation, neoplastic transformation and apoptotic regulation [148].  In-
vitro cell culture models have also implicated PDCD-4 in inhibition of tumorigenesis, through down 
regulation of carbonic anhydrase II and urokinase receptor [245].  Confirmation of its tumor suppressive 
role has been demonstrated in mouse models in which overexpression of PDCD-4 in the epidermis led to 
significant reductions in skin carcinogenesis [153].   Expression analysis of PDCD-4 has shown that it is 
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down regulated in a variety of tumors providing additional confirmation of PDCD-4’s function as a tumor 
suppressor [135, 220, 246].  In the single study examining miR-21 target genes in ULM, Pan et. al. [247] 
observed a slight decline in PDCD-4 mRNA levels in cultured primary leiomyoma cells compared to 
cultured myometrial cells, while paradoxically, showing that PDCD-4 mRNA levels were increased in a 
transformed leiomyoma cell line and in a leiomyosarcoma cell line, inconsistent with its role in tumor 
suppression.   This study, however, did not address whether PDCD-4 protein expression was regulated by 
miR-21 in these cell lines [247].  Lastly, no study has examined PDCD-4 expression patterns in isolated 
leiomyoma or myometrial tissue. 
 This study investigated miR-21 and PDCD-4 expression patterns in hTert-immortalized 
leiomyoma (UtLM) and myometrial (UtM) cell lines as well as in leiomyoma and myometrial tissues.  
Additionally, we determined if miR-21 could post-transcriptionally regulate PDCD-4 and whether miR-
21 could elicit effects on apoptosis or translation within the immortalized cell lines.  Our results showed a 
distinct pattern of protein expression for PDCD-4 in leiomyoma tissues when compared to autologous 
myometrial tissues.  Moreover, we observed that miR-21 affected global translation and regulation of 
apoptosis within myometrial and leiomyoma cells, and PDCD-4 did not reflect the anticipated inverse 
correlation with miR-21 levels.   
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3.  Experimental Procedures 
Tissue Samples 
Myometrial and leiomyoma tissue samples were obtained from healthy premenopausal women with 
symptomatic leiomyomas at the time of elective hysterectomy at Carle Foundation Hospital (Urbana, IL).  
All tissues were collected under consent for use of discarded human tissue that was approved by the 
Institutional Review Board at the University of Illinois at Urbana-Champaign and Carle Foundation 
Hospital.  Each tissue sample was assigned an arbitrary identification number on the day it was received 
and patient information was known only to the physician or physician’s nurse.  However, physicians 
provided information about the age of the patient and any medications.  All patients were premenopausal 
(21-50 years old) and had not been on any hormonal medications for six months prior to their 
hysterectomy.  Tissues collected were from both proliferative (53%) and secretory (47%) stages of the 
menstrual cycle.  Upon biopsy, leiomyoma (n=11) and myometrial (n=12) tissues were placed in TRIZOL 
and processed to RNA in the laboratory (18), most of these tissues were from paired tissues.  An 
additional, 11 autologous pairs of leiomyoma and myometrium tissues were used for protein analysis, 
seven of the sets of samples for the RNA and proteins samples were derived from the same patients.     
 
Cell Lines and Tissue Culture  
The hTert-immortalized leiomyoma cells (hereafter referred to as UtLM) were generated as described 
previously (38) and were generously provided by Dr. Darlene Dixon (National Institute of Environmental 
Health Sciences, Research Triangle, NC).   The hTert-immortalized myometrial cells (UtM), generously 
provided by Dr. Rainey (Medical College of Georgia, Augusta, GA), were cultured in DMEM/F12 
(Gibco, Carlsbad, CA.) supplemented with 7.5% NaHCO3, 1% antibiotic antimycotic (Gibco), and 10% 
Fetal Bovine Serum (19).  UtLM cells were cultured in MEM (Sigma, St. Louis, MO) supplemented with 
300ug/ml of G418 (Calbiochem, San Diego, CA), 1% essential amino acids (Gibco), 1% non-essential 
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amino acids (Gibco), 1% L-Glutamine, 15% FBS and 1% vitamins (Gibco).  Medium was replaced every 
2-3 days and cells were passaged using 1X Trypsin (Gibco) as needed.  
Locked nucleic acid (LNA) inhibitors were purchased from Exiqon (http://www.exiqon.com/mirna-
inhibitors). The inhibitor specific for miR-21 (LNA-miR-21), has a complementary sequence to miR-21, 
5’-CAACATCAGTCTGATAAGCT-3’ (bolded bases indicate position of locked nucleic acids), which 
binds to and blocks miR-21 action.  The non-specific inhibitor LNA-scramble, which does not recognize 
any known RNA transcripts, was used as a control.  UtM and UtLM cells were transfected in serum free 
medium (DMEM/F12 or MEM) at 85% confluence with LNA oligonucleotides (40 nM) using 
lipofectamine 2000 (Life Technologies, Grand Island, NY) per the manufacturer’s protocol.  Eight hours 
after transfection, medium was replaced with appropriate culture media for each cell line. Twenty-four 
hours after transfection, cells were harvested and RNA was isolated using Trizol (Ambion, Carlsbad, CA) 
per manufacturer’s protocol and stored at -80
0
 C until use.  Cells were lysed in a hyptonic buffer 
containing 20mM NaCL, 25mM Tris-HCl and 0.1% Triton X-100.  Lysates were centrifuged at 10,000g 
for 10 minutes to pellet cellular debris.  The protein supernatant was stored at -80
0
 until use.            
 
Western Blotting 
Protein concentration was determined for each sample using the Bio-Rad protein assay (Bio-Rad 
Laboratories, Hercules CA).  Proteins (15 ug/sample) were denatured by diluting the appropriate volume 
in 4X Sample Buffer (4ml of glycerol, 0.8g of SDS, 2.5 ml of 1M Tris-HCl, 8ml of H20, .05% w/v 
bromophenol blue) and heating at 95
o
 C for 5 minutes.  Proteins were resolved in a 10% SDS PAGE gels 
in 1X running buffer (4.5g Tris-Base, 21.6 glycine, 2g SDS, 2L dH2O) and then transferred to PVDF 
membrane using transfer buffer (6.06g of Tris-Base, 28g glycine, 0.2g SDS, 1600 ml dH2O, 400 ml 
MeOH).  Membranes were blocked in 5% milk in 1X TBS-T for 1 hour. Primary antibodies were 
incubated with membranes overnight at 4
0
 C at 1:1000 dilution in 5% milk in 1X TBS-T and appropriate 
secondary antibodies were incubated for 1 hour at room temperature with membranes at 1:10000 dilution 
in 5% milk in 1X TBS-T.  Membranes were washed 3X10 minutes before and after secondary antibody 
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incubation in 1X TBS-T. West Pico chemiluminescent substrate (Thermo Scientific Waltham, MA) was 
used to visualize the protein antibody complexes.  Primary antibodies included 2-PDCD-4 antibodies 
(ProSci, Poway, CA and Sigma, St.Louis, MO), actin (Santa Cruz Biotechnology, Santa Cruz, CA), 
phospho-EF2, and cleaved caspase 3 (Cell Signaling, Danvers, MA).  Secondary antibody used for all 
westerns other than actin was donkey anti-Rabbit IgG-HRP (GE Healthcare, Little Chalftont, UK.).  
Secondary antibody used for the Actin westerns was donkey anti-Goat IgG-HRP (Santa Cruz 
Biotechnology, Santa Cruz, CA.) 
 
Quantitative RT-PCR      
Total RNA (250ng) was reverse transcribed using the miScript Reverse Transcription Kit per the 
manufacturer’s protocol (Qiagen, Hilden, Germany).  Samples were diluted 1:10 in dH20 for qRT-PCR, 
which was performed on an Applied Biosystems HT7900 sequence detector (Foster City, CA).  Primer 
sets for U6 (forward primer CTC GCT TCG GCA GCA CA, reverse primer AAC GCT TCA CGA ATT 
TGC GT) and PDCD-4 (forward primer GGC CCG AGG GAT TCT GAA, reverse primer TAT CTG 
CTC ATT TTC TAC ATC CAT TTT) and the forward primer for miR-21 (TAG CTT ATC AGA CTG 
AT) were designed using Primer Express 3.0 Software.  A universal primer from the miScript Sybr green 
PCR Kit (Qiagen) along with its forward primer was used to amplify miR-21.  Samples were run in 
following normalization with U6 (20).  The presence of a single dissociation curve confirmed the 
amplification of a single transcript and lack of primer dimers.  Standard RT-PCR using primers (forward 
primer GAAAATGCTGGGACTGAGGAA, reverse primer GACGACCTCCATCTCCTTCGCT) 
designed to span the complete PDCD-4 coding sequence was completed to determine if alternative 
spliced variants exist.   
 
 
 
95 
 
Statistics 
Band intensity of each protein was determined using Gel-Pro Analyzer software.  The mean amount (n=3) 
of each protein was determined by normalizing the intensity of the specific protein bands to that of actin.  
The mean value of each samples’ triplicate in qRT- Ct method as 
described previously (20).   Student’s T-tests were performed to determine if expression levels of protein 
and/or mRNA of interest was affected by treatment.  Statistical significance was considered at P<0.05.     
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4.  Results 
Consistent with elevated miR-21 in leiomyomas in previous studies, mature miR-21 levels in our 
leiomyoma tissues trended towards a 3.9 ± 2.9-fold increase (P=0.08) compared to normal myometrium 
(Figure VIII-1).  Expression of PDCD-4 mRNA in leiomyoma (4.2 ± 0.8; mean fold ± SEM) and 
myometrial (3.9 ± 1.1) tissues were not different (P=0.85) (Figure VIII-1).  In contrast, full-length 51 kDa 
PDCD-4 protein levels were markedly different in paired leiomyoma and myometrial tissues with 
myometrium showing barely detectable levels while leiomyoma tissues exhibited a robust signal (Figure 
VIII-1).  No differences in PDCD-4 or miR-21 by stage of menstrual cycle were noted.  Conversely, the 
paired myometrial tissues exhibited a lower molecular weight immunoreactive band that was not evident 
in the leiomyoma tissues (Figure VIII-1 and Figure VIII-5).  To ensure this lower band was not an 
artifact, another PDCD-4 antibody (Sigma) was used (Figure VIII-5) and a similar pattern of 
immunoreactive bands was present, albeit the signal was not as robust for the lower band in the 
myometrium.  In addition, leiomyomas exhibited a number of additional immunoreactive bands below the 
predicted full length 51 kDa PDCD-4 again with both antibodies (Figure VIII-1 and Figure VIII-5).  
 Immortalized myometrial cells (UtM) and leiomyoma cells (UtLM) were assayed for their 
relative expression of PDCD-4 mRNA/protein and miR-21.   Unlike myometrial and leiomyoma tissues 
obtained from patients, both cell lines expressed the 51 kDa isoform, but consistent with the tissues, the 
UtLM cells had higher levels (1.4-fold) than UtM cells (Figure VIII-1).  Again consistent with tissues, the 
lower molecular wt immunoreactive band was higher (2-fold) in UtM cells (Figure VIII-1).  In addition, 
similar to patient-derived leiomyomas, a number of immunoreactive bands between 50 and 32 kDa were 
observed in the UtLM cells with minor evidence of these intermediate bands in the UtM cells (Figure 
VIII-1). RT-PCR for the full length mRNA failed to show differences between the myometrial and 
leiomyoma tissues.   Direct comparison of PDCD-4 protein expression between tissue samples and 
immortalized cell lines revealed that the expression pattern of the normal myometrial tissues closely 
resembles that of the UtM cells while that of the leiomyoma tissues closely resembles that of the UtLM 
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cells.  PDCD-4 mRNA expression did not differ significantly between the cell lines (Figure VIII-1), while 
mature miR-21 expression was 4-fold greater in UtLM cells compared to UtM cells (Figure VIII-1).  
Since PDCD-4 is a known functional target of miR-21 in other cell lines, we analyzed PDCD-4 
expression after inhibition of miR-21 in both the UtM and UtLM cell lines (Figure VIII-6 confirms the 
loss of mature miR-21 levels following LNA-miR-21 treatment of UtM and UtLM cells).  Inhibition of 
miR-21 in UtM cells increased expression of the 51 kDa PDCD-4 isoform 2.5-fold (Figure VIII-2), 
whereas inhibition of miR-21 in UtLM cells increased the expression of the 51 kDa PDCD-4 isoform 
only 1.5-fold (Figure VIII-2). While loss of miR-21 action following LNA-miR-21 treatment impacted 
PDCD-4 protein synthesis, we observed no effect on PDCD-4 mRNA expression in either UtM or UtLM 
cells (Figure VIII-6).   Consistent with miR-21's anti-apoptotic activity, inhibition of miR-21 activity 
increased the level of cleaved caspase-3, a marker of apoptosis in both UtM and UtLM cells (Figure VIII-
3).  In addition to its effects on PDCD-4 and apoptosis, we also examined whether miR-21 could affect 
global protein translation by measuring a key regulatory step, the phosphorylation of elongation factor-2 
(EF2), a protein critical for protein translation (21).  Increased levels of phosphorylated EF-2 in 
myometrial cells compared to the leiomyoma cells (Figure VIII-4) would be consistent with greater 
overall protein expression by the leiomyoma cells. Inhibition of miR-21 in UtM and UtLM cell lines 
caused a 6-fold and 3-fold induction of phosphorylated EF-2, respectively, indicating that miR-21 
expression can positively affect translation in both cell lines (Figure VIII-4).   
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Figure VIII-1.  Differential expression of PDCD-4 and miR-21 in leiomyoma and myometrial tissues and 
immortalized cell lines, UtLM (leiomyoma) and UtM (myometrial).  A) Western analysis of PDCD-4 
isoforms in 3 representative paired leiomyoma and normal myometrial samples of a total of 11 examined 
are shown.  B) Western analysis of PDCD-4 isoforms in UtLM and UtM cell lines. *Means ± SEM (n=3) 
for the 51 kDa band between cells types are different (P<0.05).  C) qRT-PCR analysis of miR-21 and 
PDCD-4 mRNA levels in UtLM and UtM cell lines. *Means ± SEM (n=3) are different (P<0.05) between 
UtLM cells and UtM cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
Figure VIII-1 
 
                                         
                                       
                     
 
 
100 
 
Figure VIII-2.  MiR-21 regulation of PDCD-4 in UtM and UtLM cells. Locked nucleic acid (LNA) 
oligonucleotides complementary to miR-21 (LNA-miR-21) or a scrambled (LNA-scr) control were 
transfected into UtM cells (A) or UtLM cells (B). *Means ± SEM (n=3) PDCD-4 (51 kDa isoform) levels 
normalized to actin are different (P<0.05) between LNA-scramble and LNA-miR-21 treated cells.   
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Figure VIII-2 
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Figure VIII-3.  Knockdown of miR-21 in UtM and UtLM cells increases cleaved caspase-3. Locked 
nucleic acid (LNA) oligonucleotides complementary to miR-21 (LNA-miR-21) or a scrambled (LNA-
scramble) control were transfected into UtM cells (A) or UtLM cells (B).  Western analysis showed a 
significant induction of cleaved caspase-3 in the LNA-miR-21 treated UtM and UtLM cells across 3 
independent experiments. 
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Figure VIII-3 
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Figure VIII-4.  Expression of phosphorylated EF-2 in UtM and UtLM cells following knockdown of 
miR-21.  A) Basal ph-EF2 expression levels in UtM cells and UtLM cells. *Means ± SEM (n=3) ph-EF2 
levels normalized to actin are different (P<0.05).  B) Locked nucleic acid (LNA) oligonucleotides 
complementary to miR-21 (LNA-miR-21) or a scrambled (LNA-scr) control were transfected into UtM 
cells or UtLM cells. *Means ± SEM (n=3) ph-EF2 levels normalized to actin are different (P<0.05) 
between LNA-scramble and LNA-miR-21 treated cells.  
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Figure VIII-4 
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5.  Discussion 
As part of our examination of miR-21’s role in uterine fibroid pathophysiology, we uncovered that 
PDCD-4, a potential target of miR-21, exhibited a dramatic increase in protein expression in leiomyoma 
tissues compared to autologous myometrial tissues, with no corresponding change in mRNA levels.  Our 
results also revealed that the pattern of PDCD-4 expression, as well as that of miR-21 were preserved in 
immortalized myometrial and leiomyoma cells, enabling us to investigate miR-21’s potential role in 
regulating PDCD-4 protein levels.   Using these cells we demonstrated that miR-21 down regulates 
PDCD-4 protein expression. However, this is likely a minor effect because even though levels of miR-21 
were elevated in leiomyoma tissues (our findings and others 9-11), the expression of PDCD-4 protein in 
leiomyomas was increased as well.  We further demonstrated that miR-21 is able to exert independent 
effects in myometrial/leiomyoma cells (i.e., increased cell growth and blockade of apoptosis) that are 
consistent with the pathophysiology of this disease.   
 Loss of PDCD-4 is associated with tumor progression and PDCD-4 reintroduction into cells can 
block neoplastic growth [221].  Based on these studies we were surprised to detect increased expression 
of PDCD-4 protein in leiomyoma tissues in our study, particularly, because we expected the elevated 
levels of miR-21 to decrease protein levels by blocking mRNA translation.  Recent studies indicate that 
PDCD-4 exhibits decreased expression in metastatic tumors in humans and mice and that restoring 
expression blocks the metastatic (invasive) potential of tumor cells [148, 221].   Thus, our unexpected 
finding of highly elevated PDCD-4 protein in leiomyomas raises the possibility that its role in these 
benign tumors may be to prevent malignant progression. Perhaps loss of PDCD-4 may occur in 
metastasizing leiomyomas or in leiomyosarcomas. What drives the increased PDCD-4 protein expression 
in leiomyomas remains unknown.  While our study indicated that this was not likely a transcriptional 
response (i.e., equivalent PDCD-4 mRNA in leiomyoma and myometrial tissues), a large expression 
analysis study [248] of paired human uterine leiomyoma and myometrial tissue was able to show a slight 
1.32-fold (P<0.05) increase in PDCD-4 mRNA levels in leiomyoma over myometrial tissues 
107 
 
(GSE13319).  This slight increase in PDCD-4 mRNA expression, however, does not explain the marked 
differences in protein levels we observed.   
 Functional studies of the 51 kDa PDCD-4 have revealed that it can inhibit cap dependent 
translation as well as regulate RNA metabolism [249].   We were unable to find reported evidence of the 
low molecular weight band observed in myometrial tissues in any other tissues.  We also observed that 
leiomyoma tissue and immortalized-leiomyoma cells exhibited the presence of numerous immunoreactive 
bands below the full length 51 kDA isoform.  These may be the result of alternative splicing or 
proteasomal degradation in leiomyoma tissues.  Recently, Schmid et al., [250] proposed that proteosomal 
degradation of PDCD-4 requiring activation of the mTOR pathway is involved in inflammation-mediated 
tumor progression.    The exact nature of these immunoreactive products (alternative spliced protein, 
degradation product) remains to be determined, yet our simple RT-PCR analysis was unable to detect 
different mRNA isoforms.  Determination of the PDCD-4 isoform composition within biopsies may have 
clinical value for characterization of the metastatic potential of leiomyomas.  
 The combined differential expression of miR-21 and PDCD-4 protein in the UtLM (leiomyoma) 
cells compared to UtM (myometrial) cells in a manner consistent with the expression in autologous pairs 
of primary tissues indicates that these cell lines are a useful model system for studying miR-21 and 
PDCD-4 expression and their potential interactions.  Previous investigations have revealed that miR-21 
post-transcriptionally regulates PDCD-4 in a number of cancer cell lines, including MCF-7, Colo206f and 
MDA-MB-231 [138, 140, 146].  Inhibition of miR-21 in both UtLM and UtM cells increased expression 
of the 51 kDa isoform of PDCD-4 protein, while having no effect on the lower immunoreactive molecular 
weight band.  The lack of change in PDCD-4 mRNA levels indicates that miR-21 post-transcriptionally 
regulates PDCD-4 primarily through a block of translation and not mRNA degradation.  The PDCD-4 
mRNA results of our study, contrast those of Pan et al [247], who showed that inhibition and 
overexpression of miR-21 in several uterine smooth muscle cell lines could impact PDCD-4 mRNA 
levels.  Possible differences in experimental systems (i.e., cell lines or type of inhibitors used) may 
account for these differences, yet our results from the UtM-immortalized cells are consistent with our 
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tissue-derived data.  Inhibition of miR-21 resulted in reduced induction of PDCD-4 protein in UtLM cells 
compared to UtM cells, possibly due to the higher initial basal levels of PDCD-4 in UtLM cells or 
because miR-21 levels may have less regulatory impact in UtM cells.   The higher basal expression levels 
of miR-21 in UtLM cells may also explain why inhibition of PDCD-4 with a fixed amount (albeit a 
saturating amount) of the blocking LNA-miR-21 was less effective.  Thus, while showing for the first 
time that miR-21 can modulate PDCD-4 protein levels in leiomyoma cells in culture, our experiments 
suggest that miR-21 is in of itself, not a potent regulator of PDCD-4 expression in leiomyoma tissues as 
the levels of PDCD-4 should have decreased in leiomyoma tissues rather than increased.  
 Earlier array studies revealed that miR-21 has higher expression levels in leiomyomas when 
compared to normal myometrium [202-204].  Our study supports these previous observations, although 
the 3.9-fold induction we observed only trended toward significance (P=0.08).  This discrepancy could be 
a result of our smaller sample sizes (n=12) compared to the larger sample sizes (n>50) used in previous 
studies where miR-21 was identified as upregulated.  Significantly, the higher expression of miR-21 in 
leiomyoma tissues was consistent with the findings of in vitro cell culture results that showed elevated 
miR-21 expression levels in UtLM cells.  This increased level of expression of miR-21 in leiomyoma 
tissues may provide limited regulatory control of PDCD-4 expression in vivo as compared to the greater 
regulation seen in our in vitro results.  Since miR-21 overexpression in leiomyoma tissues and 
immortalized leiomyoma cells did not have a major impact on PDCD-4 expression, we also examined 
whether it might be influencing other cellular processes that had previously been reported [133, 139, 251].  
Studies have shown increased expression of Bcl-2, a cell survival gene, and TNFα, a gene known to 
induce apoptosis in leiomyomas compared to normal myometrium [252].  Wu et al., found that there was 
no difference between the apoptotic index of leiomyoma and myometrial tissues [253], suggesting that 
Bcl-2, TNFα as well as other yet-to-be identified proteins (factors) are functioning to maintain 
homeostatic relationship in leiomyoma tissues.   Our study sought to determine whether miR-21, an 
oncomir known to inhibit apoptosis, might play a role in regulation of apoptosis in UtLM and/or UtM 
cells.  Knockdown of miR-21 caused a robust increase in cleavage of caspase 3, a marker for programmed 
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cell death, in both cell lines.  This finding indicates that elevated levels of miR-21 may act to prevent 
programmed cell death in rapidly growing leiomyomas.  It is possible that miR-21 contributes to this 
apoptotic homeostatic balance through indirect regulation of Bcl-2 and/or TNFα.  Further studies are 
needed to determine if these genes may be direct or indirect targets of miR-21, or whether miR-21 
impacts other apoptotic genes.  
 Previous investigations have also shown increased PCNA and Ki67 staining in leiomyomas over 
that of normal myometrium, indicating that leiomyoma is a more highly proliferative tissue [184, 253, 
254].  Studies have also implicated the involvement of the mTOR pathway in the development of 
leiomyomas.   Makker et al., [255] showed that mTOR signaling is increased in leiomyomas, while Yin et 
al. [256], revealed that estrogen requires mTOR to drive G1 cell cycle progression in leiomyomas.  
Elongation factor 2 (EF2), a gene that functions in protein synthesis and a downstream mediator of the 
mTOR pathway, is involved in control of global translation.  In its un-phosphorylated form, EF2 is able to 
bind to the ribosome and translocate the mRNA-tRNA complex from the A site to the P site, and thus 
promote translation [100, 249].   Our study revealed that inhibition of miR-21 in both UtLM and UtM 
cells increased phosphorylation levels of EF2, supporting the hypothesis that basal levels of miR-21 in 
both cell lines are critical for maintaining EF2 in its un-phosphorylated state thereby allowing increased 
translation.  These findings indicate that miR-21 may promote cell proliferation/growth through 
regulation of upstream mediators of EF2 phosphorylation.       
 Overall, the findings from our studies indicate that PDCD-4 exhibits a unique expression profile 
,with almost complete absence of the full length PDCD-4 protein in normal myometrium, combined with 
unexpected, high overexpression in leiomyomas.  This would suggest that PDCD-4 does not act as a 
typical tumor suppressor gene in leiomyomas as has been shown for several malignant tumors.   Future 
studies, examining the role that steroids and other key regulatory molecules play in the regulation of 
PDCD-4 expression may prove to be highly informative.  Additionally, a possible beneficial role in 
maintaining leiomyomas as benign non-metastatic tumors can be envisioned based on previous studies.   
Our studies also demonstrated that while the elevated levels of miR-21 found in leiomyoma tissues had a 
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limited effect on PDCD-4 expression; it may yet play key roles in promoting translation to stimulate 
growth of the leiomyoma cells.  Lastly, the similar patterns of expression of miR-21 and PDCD-4 
between the immortalized cell lines and in vivo tissues, supports the concept that UtLM and UtM cells are 
useful model systems for studying miR-21 and PDCD-4 function and regulation.    
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6  Supplemental Data 
Figure VIII-5.  PDCD-4 expression across paired normal and leiomyoma tissue using polyclonal anti-
PDCD-4 antibody from (A) Sigma and (B) ProSci.  P represents individual patients. 
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Figure VIII-5 
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Figure VIII-6.  (A) Efficacy of miR-21 knockdown after LNA-21 treatment in UtM and UtLM cells.  (B) 
PDCD-4 mRNA levels after LNA-NS (scrambled) and LNA-21 treatment in UtM and UtLM cells.  
**means +/- standard error of the mean (n=3) miR-21 levels normalized to U6 are different (P<.01) 
between LNA-miR-21 (LNA-21) and LNA-scrambled (LNA-NS). 
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Figure VIII-6 
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IX. Chapter 5: Concluding Statements 
A significant number of studies have investigated the role of microRNA-21 (miR-21) in cancer through 
identifying its direct targets and investigating its functions.  The current investigation extends and 
broadens the understanding of miR-21 through identifying its direct targets in a physiological context.  
This study is the first to identify a miR-21 direct target in a physiological cell line and it is the first to 
implicate Apobec3 and USP30 as potential targets and confirm ISX as miR-21 direct target.  Additionally 
the role of miR-21 and one of its most studied direct targets, PDCD-4, was investigated in ULMs.  While 
miR-21 was capable of modest inhibition of PDCD-4 expression in our in vitro assays, our study revealed 
that both PDCD-4 and miR-21 were overexpressed in ULMs when compared to healthy myometrial 
tissue.  This is inconsistent with many previous studies that have shown that miR-21 inhibits PDCD-4 
expression.  Induction of PDCD-4 in ULMs is also atypical as PDCD-4 is consistently shown to be lost in 
tumors.  Together these findings have revealed novel miR-21 direct targets in ovarian granulosa cells and 
has shownthat cellular and tissue context can have dramatic effects on miR-21 action on target genes, and 
lastly that PDCD-4 may have unique functional roles in the etiology of ULMs.           
 
Identification of miR-21 Direct Targets in Granulosa Cells 
 The foundational work that drove much of the studies in this dissertation was the findings that 
miR-21was LH regulated and a critical factor in maintaining optimal ovulation rates and preventing cell 
death in granulosa cells.  What was unknown was the mechanism by which miR-21 carried out these 
functions.  The purpose of this study was to begin to elucidate this mechanism through identification of 
miR-21 direct targets.  The methodological approach used was to identify candidate genes through 
examining mRNA that are under miR-21 regulation that also have potential miR-21 binding sites in their 
3’UTRs.  Once candidate genes were identified, a select number were screened, using 3’UTR luciferase 
reporter assays, to determine if miR-21 could modulate luciferase levels.  Luciferase activity for the 
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3’UTRs from the apolipoprotein mRNA editing enzyme catalytic polypeptide 3 (Apobec3), Ubiquitin-
specific protease 30 (USP30) and intestinal-specific homeobox (ISX) genes were shown to be regulated 
by miR-21 in mouse granulosa cells. 
 Each of these genes has been shown to function in roles that may have significance in granulosa 
cells.  USP30 plays a role in mitochondrial morphology and its deletion leads to interconnected and 
elongated microtubular structures [208].  Studies in the ovary have shown that appropriate mitochondrial 
morphology is critical for optimal steroid output [209-211].  Apobec3 functions in innate immunity 
against retroviruses and is known to regulate many different immune markers [212].  A variety of 
immunological markers are also under LH regulation in granulosa cells following the LH surge [213-
214].  Intestinal-specific homeobox (ISX) has been shown to regulate scavenger receptor class B type 1 
(SRB1) in the intestine [215].  Previous studies have revealed that SRB1 is regulated by LH and is a 
critical factor in steroidogenesis [216-217].  It is possible that miR-21 is directly targeting Apobec3, 
USP30 and ISX to regulate these functions in granulosa cells.  In this way, this project has not only 
identified unique miR-21 direct targets but it also implicated this microRNA in novel functional roles, 
already known to be important for normal ovarian physiology.   
 Additional research needs to be performed to determine if Apobec3, USP30 and/or ISX are bona 
fide miR-21 direct targets.  Specifically, while this project revealed that miR-21 does regulate each genes’ 
3’UTR, further study is necessary to determine if this regulation is direct or indirect.  Future studies 
should also include the identification of additional miR-21 direct targets.  This project revealed the 
efficacy of examining steady-state mRNA as a means to identify miR-21 direct targets.  Examination of 
the candidate genes identified in this study should, therefore, reveal more miR-21 direct targets.  
Sequence analysis from the bioinformatic algorithm, miRanda, identified a miR-21 binding site on the 
3’UTR of Apobec3 and ISX (miR-21 direct targets identified in this study), which had 6 and 7 
consecutive bases, respectively, that had perfect complementarity to the 5’ end of miR-21 (Figure IX-1). 
Perfect complementary base pairing at the 5’ end of the microRNA is this most prominent mechanism of 
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microRNA/mRNA interaction and sequence analysis of the putative miR-21 binding site of Apobec3 and 
ISX is supportive of these findings.  It may, therefore, be useful for future studies to test genes that have 
the 5’ dominant base pairing with miR-21 as top candidates for miR-21 direct targets. 
 Since it is likely that miR-21 directly targets multiple genes in granulosa cells, identification of 
additional direct targets is critical for fully elucidating the fundamental molecular events under miR-21 
regulation.   Identification of these targets is important for understanding the mechanism by which miR-
21 carries out its anti-apoptotic and pro-ovulatory functions in granulosa cells.      
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Figure IX-1.  Miranda sequence analysis for putative miR-21 binding sites for Apobec3 and ISX.  
Apobec3 and ISX contain 6 and 7 consecutive bases, respectively, that have perfect complementarity with 
the 5’ end of miR-21. 
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Figure IX-1 
 
      
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     3' agUUGUAGUCA-GA-CU-AUUCGAu 5' mmu-miR-21 
          ||| ||| | || || ||||||  
     5' ggAAC-UCACUACUAGACUAAGCUg 3' Apobec3 
 
     3' aguuguagUCA-GAC-UAUUCGAu 5' mmu-miR-21 
                ||| | | |||||||  
     5' ggggaugaAGUCCAGAAUAAGCUg 3' Isx 
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Identification of intestinal-specific homeobox (ISX) as a miR-21 direct target 
 The luciferase assay screen from chapter 2 implicated ISX as miR-21 direct target.  Results in 
chapter 3 showed that miR-21 regulation of the ISX 3’UTR was direct and that miR-21 regulated ISX 
protein expression in granulosa cells.  Together these findings show that ISX is a bona fide miR-21 direct 
in granulosa cells. 
 Intestinal-specific homeobox is a transcription factor originally identified in the intestinal 
epithelium [227].  An ISX knockout study in which β-galactosidase was knocked in to the ISX locus 
revealed that ISX expression exists throughout the epithelial cells from the duodenum to the proximal 
colon [228].  Expression analysis from this same study revealed that there was significant induction of 
scavenger receptor class B type (SRB1) and  β,β-carotene 15,15′-monooxygenase 1 (BCMO1) mRNA 
levels throughout the duodenum and jejunum of the ISX knockout mice [228].   In a subsequent study it 
was shown that retinoic acid signaling lead to upregulation of ISX expression, which caused inhibition of 
retinoic acid receptor α (RARα) and BCMO1 [215].  Withing the intestine, SRB1, BCMO1 and RARα are 
important factors in lipid uptake and vitamin A metabolism in the intestine [257-259], so ISX regulation 
of these genes suggests that this transcription factor is regulating these functions in the intestine.  
 In addition to their roles in the intestine SRB1, BCMO1 and RARα have been implicated in roles 
in the ovary.  Highly expressed in both the liver and rodent steroidogenic cells, SRB1 is known to 
mediate cholesterol uptake [223, 224, 260].  SRB1 is also capable of recognizing both negatively charged 
liposomes and apoptotic cells [260]. β,β-carotene 15,15′-monooxygenase 1 (BCMO1) functions in many 
tissues as the key enzyme for beta carotene metabolism [228, 262-264].  Reduced vitamin A causes 
induction of BCMO1 expression [265].  Studies in trout have shown that BCMO1 is expressed in the 
ovary and that it has higher expression in juvenile ovaries compared to adult [236]. β,β-carotene 15,15′-
monooxygenase 1 has also been shown to function development and differentiation as well as 
embryogenesis [266]. Retinoic acid receptor  (RAR) has high expression in both the human and rat 
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ovary, mostly being localized to nuclear compartments within cells [267].    It plays an essential role in 
cellular growth regulation, differentiation and cell death across many tissues during fetal development.  It 
is also important for maintaining the viability of germ cells during fetal oogenesis in the mouse [235].  
Also retinoic acid signaling via regulation of Stra8 is essential for meiotic re-entry of ovarian germ cells 
[268] [225].  
In this study each of these genes, SRB1, BCMO1 and RAR were all shown to be negatively by ISX in 
granulosa cells.   This suggests the possibility that ISX is regulating, in granulosa cells, the functions 
under SRB1, BCMO1 and RAR control.  Since miR-21 directly targets ISX, miR-21 may be the master 
regulator of SRB1, BCMO1 and RAR as well as their functions.   Studies done prior to this 
investigation showed that miR-21 is regulated by the LH surge.  If the gene pathway identified in cultured 
granulosa cells in this project is at play in vivo, the LH surge may function to upregulate SRB1, BCMO1 
and RAR in granulosa cells through induction of miR-21 and subsequent inhibition of ISX (Figure IX-
2).  Previous research has already shown that LH causes induction of SRB1 in granulosa cells and this 
regulatory event is important for increased steroidogenesis.  Revealed in this work, is the potential 
mechanism by which LH might upregulate SRB1 and induce steroidogenesis in granulosa cells.   The LH 
surge also functions to cause meiotic resumption in the oocyte.  Retinoic acid receptor  is known to play 
a critical role in this process.  Potentially LH, through induction and inhibition of miR-21 and ISX, 
respectively, upregulates RAR in granulosa cells and through paracrine interaction with the oocyte (a 
well-known signaling mechanism between granulosa cells and the oocyte) leads to meiotic re-entry.  
Shown in figure IX-2 is a diagram of this proposed gene regulatory mechanism in granulosa cells.  
BCMO1 may also play a role in carrying out LH function.  However, since what, if any, function it 
carries out in the periovulatory period is not known, it is difficult to hypothesize its potential LH mediated 
role.     
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Figure IX-2.  Proposed LH pathway in granulosa cells.  The LH surge causes induction of miR-21 
leading to repression of ISX.  Inhibition of ISX causes induction of SRB1 and RAR, genes known to 
function in steroidogenesis and meiotic resumption in the ovary. 
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Figure IX-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LH miR-21 ISX SRB1 and RAR 
Meiotic resumption in oocyte and increased 
steroidogenesis in granulosa cells????? 
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Further research could be pursued to test this proposed model.  First it should be determined if ISX is an 
in-vivo miR-21 direct target in granulosa cells specifically after the LH surge.  Additional studies could 
also analyze the expression of BCMO1 and RAR after the LH surge (LH regulation of SRB1 has already 
been determined) and if these genes including SRB1 are regulated by miR-21 and/or ISX during the 
periovulatory period.  Together these assays would determine if the pathway identified in cultured 
granulosa cells in this study also exists in granulosa cells in-vivo. 
Subsequent studies could then be performed to identify the functional consequences of this gene pathway 
in the granulosa cells and the ovary.  Assays in cultured granulosa cells could test, for instance, if 
dysregulation of ISX affects SRB1 and/or steroidogenesis.  Culture studies could also be pursued to 
determine if ISX, through regulation of SRB1, affects vitamin A uptake as this is a known mechanism of 
vitamin A uptake in the intestine.  In-vivo studies could be performed to determine if ISX, through 
regulation of RAR in granulosa cells, impacts meiosis in the oocyte through paracrine signaling between 
the oocyte and granulosa cells.  And while investigating the potential impact on embryogenesis of ISX 
through regulation of BCMO1 is outside the scope of this project it is useful to keep in mind that this 
control mechanism may exist in the ovary.  More generally miR-21, ISX and the genes it regulates may 
have important functions outside of the window of events that occur in cultured granulosa cells and after 
the LH surge.   
Ultimately these studies will determine the functional consequences of genes regulated by miR-21.  This 
will tie together the regulatory pathway under miR-21 control with its impact on granulosa cell and 
ovarian physiology.  Together findings from this project combined with additional mechanistic and 
functional studies suggested above will elucidate the molecular and physiological events critical for 
understanding the impact of miR-21 in granulosa cells and the ovary.      
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MicroRNA-21 and programmed cell death 4 in Human Uterine Leiomyomas 
 Human Uterine Leiomyomas (ULMs) are benign tumors of the myometrium that can cause 
abnormal bleeding, pelvic pressure/pain and can lead to reproductive dysfunction.  There is a 70-80% 
lifetime incidence rate for women throughout their reproductive life and they are the leading cause of 
hysterectomies causing over 200,000 annually in the United States.  Hormones, growth factors and 
genetics are known to play a role in ULMs but the etiology and biological mechanisms that give rise to 
the disease are not well understood.  Profiling experiments have shown that ULMs have a distinct 
microRNA profile and that miR-21 is highly overexpressed in this pathology.  Based upon this latter 
finding, this project sought to investigate the role of miR-21 in ULMs.   
 This study showed that knockdown of miR-21 in UtLM cells (a cell line derived from ULMs) 
caused induction of cleaved caspase 3 and phospho-EF2.  Together these findings indicate that miR-21 is 
playing an anti-apoptotic role and promoting global translation.  MiR-21 has been shown to function in 
these roles in other tissues and studies in ULMs have shown that the tissue is highly proliferative.  
Together these findings suggest that miR-21 may have an anti-apoptotic role and promote global 
translation in ULMs.   
 Further study in this investigation that miR-21 inhibited expression of PDCD-4 (one of miR-21’s 
most functionally relevant direct targets) in the UtLM cell line.  However miR-21’s regulatory control 
over PDCD-4 was minor and it was significantly less than miR-21’s inhibition in UtM cells (a cell line 
derived from healthy myometrial tissue).  If these cell lines are adequate model systems for studying miR-
21 and PDCD-4 interaction in the tissues from which they derive, this finding means that miR-21 is 
exerting less regulatory control over PDCD-4 in ULMs when compared to healthy myometrial tissue.  
Most significantly this study revealed that PDCD-4 is highly upregulated in ULMs when compared to 
healthy myometrial tissue.  This finding is quite unique as PDCD-4 is a well-studied tumor suppressor 
that is inhibited in metastatic tumors.  Functional studies in mouse models have shown that PDCD-4 
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inhibits metastases.  Potentially overexpression of PDCD-4 in ULMs, a benign tumor, is functioning in 
this same capacity.  Another unique finding from this study is that overexpression of PDCD-4 in ULMs is 
commensurate with the induction of miR-21.  PDCD-4 and miR-21 are inversely expressed across many 
cancers and miR-21 directly targets PDCD-4 in many cancer cell lines.  So comcomitant induction of 
both PDCD-4 and miR-21 in ULMs indicates that PDCD-4 is outside of the regulatory control of miR-21 
as it is upregulated in this uterine disease.  
Future studies should  test both PDCD-4’s functional role and its mechanism of induction in ULMs.  To 
test this hypothesis that PDCD-4 is preventing metastasis in ULMs, assays could be performed in UtLM 
cells to determine if PDCD-4 regulates migration in this cell line.  If PDCD-4 does regulate cell migration 
in UtLM cells, one could hypothesize that PDCD-4 is carrying out this same function in ULMs.  A further 
study that could be pursued to test PDCD-4’s potential impact on migration is to compare its expression 
patterns between ULMs and uterine leiomyomsarcomas, which are metastatic uterine tumors.  If, for 
example, PDCD-4 expression is inhibited in leiomyosarcomas vs. ULMs, this finding would be consistent 
with the hypothesis that PDCD-4 is inhibiting migration in ULMs. 
To identify the mechanism of PDCD-4 induction in ULMs  microRNA, other than miR-21, could be 
examined.  Potential candidates would include those that are inhibited in ULMs vs. healthy myometrium 
and are complementary to a sequence on the 3’UTR of PDCD-4.  Once candidate microRNA were 
identified, 3’UTR luciferase analysis, similar to those performed in this study, could be performed in 
UtLM cells to determine if the microRNA could bind the PDCD-4 3’UTR.  Also, polysomal gradient 
analysis could be performed on UtM and UtLM cell lines (cell lines that showed differential PDCD-4 
expression patterns in this study) to determine if PDCD-4 migration patterns within the gradient were 
different between the cell lines.  This approach would determine if the mechanism of PDCD-4 induction 
in UtLM cells is via translation control.  Together these studies would reveal the functional importance of 
PDCD-4 and the regulatory pathway of PDCD-4 induction in ULMs. 
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Results from these future studies may, in addition to adding to our understanding of the role of PDCD-4 
ULMs, impact our understanding of tumor biology.  As previously mentioned PDCD-4 is inhibited in 
metastatic tumors.  What is not known though is expression patterns of PDCD-4 across benign tumors.  
This study has shown that PDCD-4 is highly upregulated in ULMs, a benign tumor.  Potentially this 
PDCD-4 expression pattern persists across other benign tumors.  If so, PDCD-4 may be functioning as a 
metastatic inhibitor in tumors, a role that it plays in healthy tissue.        
   
This study has identified novel miR-21 direct targets in granulosa cells and identified novel cell 
lines (UtM and UtLM cell lines) in which microRNA regulates one of its most well-studied direct targets, 
PDCD-4.  This work has also revealed potential novel functional roles under miR-21 regulation in 
granulosa cells, which may be mediated through its regulatory control of the miR-21 direct targets 
identified in this study.  Additionally this study has revealed that miR-21 regulation of PDCD-4 (One of 
the most well-studied mechanisms of miR-21 control) is not a control mechanism in the development of 
ULMs and it  is implicated PDCD-4 in the etiology of ULMs.  Together these findings have revealed 
novel direct targets and functional roles for both miR-21 and PDCD-4 in granulosa cells and ULMs. 
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